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Abstract

Plasma medicine refers to the application of nonequilibrium plasmas at approximately body
temperature, for therapeutic purposes. Nonequilibrium plasmas are weakly ionized gases
which contain charged and neutral species and electric fields, and emit radiation, particularly
in the visible and ultraviolet range. Medically-relevant cold atmospheric pressure plasma
(CAP) sources and devices are usually dielectric barrier discharges and nonequilibrium
atmospheric pressure plasma jets. Plasma diagnostic methods and modelling approaches are
used to characterize the densities and fluxes of active plasma species and their interaction with
surrounding matter. In addition to the direct application of plasma onto living tissue, the
treatment of liquids like water or physiological saline by a CAP source is performed in order
to study specific biological activities. A basic understanding of the interaction between plasma
and liquids and bio-interfaces is essential to follow biological plasma effects. Charged species,
metastable species, and other atomic and molecular reactive species first produced in the main
plasma ignition are transported to the discharge afterglow to finally be exposed to the
biological targets. Contact with these liquid-dominated bio-interfaces generates other
secondary reactive oxygen and nitrogen species (ROS, RNS). Both ROS and RNS possess
strong oxidative properties and can trigger redox-related signalling pathways in cells and
tissue, leading to various impacts of therapeutic relevance. Dependent on the intensity of
plasma exposure, redox balance in cells can be influenced in a way that oxidative eustress
leads to stimulation of cellular processes or oxidative distress leads to cell death. Currently,
clinical CAP application is realized mainly in wound healing. The use of plasma in cancer
treatment (i.e. plasma oncology) is a currently emerging field of research. Future perspectives
and challenges in plasma medicine are mainly directed towards the control and optimization of
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CAP devices, to broaden and establish its medical applications, and to open up new
plasma-based therapies in medicine.
Keywords: plasma medicine, redox biology, low temperature plasma, reactive species, cancer,
wound healing, cold atmospheric pressure plasma (CAP)
(Some figures may appear in colour only in the online journal)

These species are transported to the discharge afterglow until
finally coming into contact with the biological targets, such
as cells or tissues. In the plasma afterglow, where air diffusion into the feed gas channel occurs, other secondary reactive
species such as O, OH, O3 , O2 − , NO, and NO2 are generated.
Figure 1 is an illustration of the processes described above [1].
Studies on the effects of plasma-generated reactive species on
biological cells showed that, depending on the operating conditions (power, gas type and flow rate, exposure time, distance
between plasma source and target, etc), different outcomes can
be achieved. These include cell death (via regulated cell death
like necrosis or apoptosis), cell detachment, change in cellular morphology and heterotrophic pathways, change in cell
motility, cell proliferation, etc [3–12].
As shown in figure 1, the plasma-generated reactive species
first encounter a gas–liquid interface where intermediate
chemical species are produced. These species then get solvated
in the liquid where other reaction by-products are generated
before direct interaction with the biological cells. Therefore,
the rate of solvation of the various species and their lifetimes
in physiological liquid need to be taken into account. Table 1
shows Henry’s law solubility constants Hcp for several species
of relevance for water at 298.15 K, while table 2 shows the
half-life of various species in physiological liquids. Note that
the larger Henry’s constant, the deeper in the liquid a specie
can penetrate with the diffusion distance roughly scaling with
the square root of the half-life. In addition, it is to be understood that Henry’s law is used here as a first estimation only,
since CAP is in a nonequilibrium state.
The biological effects of many of the above-listed reactive species are well known in cell biology. These species
can interact with cell membranes, enter the cells and
increase the intracellular ROS concentrations, which may
lead to DNA strand breaks, mitochondria damage, and may
compromise the integrity of other organelles and macromolecules (such as proteins). For example, the hydroxyl radical (OH) causes peroxidation of unsaturated fatty acids which
are a major component of the lipids constituting the cell
membrane. Another byproduct of plasma application is hydrogen peroxide (H2 O2 ), which possesses strong oxidative properties that affect, via the peroxide ions, lipids, proteins, and
DNA. Nitric oxide (NO) is another species that can be generated by plasma as it interacts with air. The NO molecule
is known to have several biological effects, which include
the regulation of immune-deficiencies, induction of phagocytosis, proliferation of keratinocytes, and regulation of collagen synthesis. In general, ROS and RNS can also trigger

1. Introduction
Nonequilibrium plasmas are weakly ionized gases which
contain charged species (electrons, positively and negatively
charged ionic species), neutral species (atomic and/or molecular radicals and nonradicals), and electric fields. These
plasmas also emit radiation that spans wavelengths in the
infrared, visible, and ultraviolet (UV) ranges. Generally, the
degree of ionization in such plasmas is less than 0.001% and
their gas temperatures are relatively low, typically less than
100 ◦ C. These plasmas can be generated at low pressures as
well as at atmospheric pressure and they are often referred to
as cold or low-temperature plasma. Low pressure plasmas have
been used for many decades in the fabrication of semiconductor components. Atmospheric pressure plasmas have typically
been used in material surface processing applications such
as making materials more hydrophilic or more hydrophobic.
Since the mid 1990s, atmospheric-pressure low-temperature
plasmas have been used in biological and medical applications, which are the main focus of this paper. In the literature, different nomenclature is used for this type of plasmas,
such as low-temperature atmospheric-pressure plasma (LTP),
nonthermal plasma (NTP), tissue tolerable plasma, and others. In this paper, we basically use the name and abbreviation
cold atmospheric-pressure plasma (CAP), which is the most
commonly used.
Investigations into the interaction of CAP with biological
cells and tissues showed that the effects of LTP are mediated
primarily by chemically reactive oxygen species (ROS) and
reactive nitrogen species (RNS) [1, 2]. Both ROS and RNS
possess strong oxidative properties and can trigger signaling
pathways in biological cells. Therefore, delivering controllable doses of these species to cells and tissues can lead to
specific biological outcomes including the onset of apoptosis,
enhancement or suppression of cell proliferation, modified cell
migration, etc. The ability to modulate cell behavior locally has
crucial implications in various CAP-based biomedical applications such as wound healing and cancer treatment [3–12].
Moreover, experiments on eukaryotic cells demonstrated that
CAP can affect mammalian cells without causing thermal or
other damage. For example, the ability of CAP to inactivate
pathogens while stimulating healthy skin cells is the basic
concept behind the use of CAP for wound healing.
The generation and transport of the reactive species generated by CAP sources proceed in several stages. Charged
species, metastable species, and other atomic and molecular
reactive species are first produced in the core plasma region.
2
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Table 1. Henry’s law solubility constant H for various species in
water at 298.15 K (source: Jet Propulsion Laboratory data base).

cell signaling cascades, modulate cell functions, and, beyond
certain concentration thresholds, can ultimately lead to cellular death pathways such as necrosis or apoptosis. Other CAP
generated agents that may play biological roles are charged
particles (electrons, negative and positive ions), photons,
as well as large electric fields that may cause irreversible cellular electroporation, allowing large molecules to enter the cells
(see section 4.1).
Since plasma produces copious amounts of the abovementioned species, it was realized early on that CAP can
be used for therapeutic purposes. Many seminal experiments
showed that this was indeed the case, which ultimately led
to the emergence and development of the field of plasma
medicine.
The use of plasma for potential therapeutic purposes dates
back to the 19th century and even earlier. However, these early
attempts were not based on in-depth scientific studies. In fact,
at that time knowledge of cell biology, redox biology, and biochemistry was at a rudimentary stage. In addition, the plasma
state was more of a mystery and not understood at all. Note
that the electron was discovered in 1897 by J. J. Thomson
while the proton was first observed by E. Goldstein in 1886
and identified as part of an atom nucleus by E Rutherford
in 1911. The definition of plasma itself was only proposed
in 1928 by I Langmuir. Moreover, it is important to realize
that for most of the 20th century low temperature plasmas
that were created in the laboratory operated mostly at low
pressure conditions. Plasmas created at atmospheric pressure were thermal plasmas such as the ones produced by arc
discharges and plasma torches, which were not suitable for
biomedical applications. However, low temperature plasmas
generated at atmospheric pressure became prevalent by the late
1980s and CAP that can safely come in contact with biological cells and tissues were developed even later. So, sciencebased ‘modern’ plasma medicine as we understand it today
only started in the mid-1990s when atmospheric-pressure,
low-temperature plasma was applied to inactivate bacteria and
when it was first realized that the reactive species generated by
the plasma played a crucial role in the observed results [13, 14].
This groundbreaking work was followed by seminal studies on
the effects of plasma on eukaryotic/mammalian cells when it
was shown that low doses of CAP can cause cell detachment
without causing necrosis and under some conditions apoptosis can be achieved [15, 16]. Following the early foundational
works mentioned above, plasma medicine, as an emerging
medical field, reached critically important milestones when the
first clinical trials on wound healing and cancer treatment were
conducted [7, 17].
Up until now, several CAP sources have been approved
for medical and cosmetic use. In 2008 the US FDA approved
R
the Rhytec Portrait
plasma jet for use in dermatology. Other
plasma devices that are in use today for various medical appliR
and the Canady Helios
cations include the Bovie J-Plasma
TM
Cold Plasma and Hybrid Plasma Scalpel. In Europe, the
medical device certification class IIa was given to the first
R
(Neoplas Med GmbH, Greifswald,
CAP-devices kINPen
R
Germany), and PlasmaDerm
(CINOGY GmbH, Duderstadt,

Species

Hcp (mol/l × atm.)
1.4 × 10−3
1.2 × 10−3
1.1 × 10−2
2.9 × 101
8.4 × 104
1.9 × 10−3
4.0 × 10−2

Argon (Ar)
Oxygen (O2 )
Ozone (O3 )
Hydroxyl (OH)
Hydrogen peroxide (H2 O2 )
Nitric oxide (NO)
Nitrogen dioxide (NO2 )

Table 2. Estimated half-life of various species in physiological
environments. Note that the actual lifetime depends on factors such
as pH and concentrations of reactive partners.

Specie

Estimated half-life

OH·
NO2 ·
O2 −
ONOO−
NO·
1
O2
H2 O2
NO2 −
NO3 −

ns
μs
s
ms
1–10 s
3–10 μs
Minutes
Minutes
Minutes

R
Germany) in 2013, and later on to SteriPlas
(ADTEC, HunR
(Terraplasma Medical, Garching,
slow, UK) and plasma care
Germany) (see section 5 of this paper).
In the last two decades the field has experienced exponential growth in term of the number of studies conducted worldwide, the number of research centers, institutes, laboratories,
and groups active in the various aspects of the field, as well
as in terms of the large number of peer reviewed publications. Finally, and as evidence that the field has steadily been
reaching a level of maturity, several books covering the fundamentals as well as the applications of CAP in medicine were
published within the last decade [18–22].

2. Plasma as a therapeutic instrument
2.1. Fundamentals of low temperature plasma

CAPs are weakly ionized gases where the electrons exhibit
kinetic temperatures much higher than that of the ions and
neutrals. Because of this particular nonequilibrium, the gas
does not undergo extensive heating. One key design feature
that characterizes CAP sources is the avoidance of the glow-toarc transition. This can be achieved by various means including judicious electrodes design and/or wave-tailoring of the
applied power. For example, barrier discharges use a dielectric or a resistive layer to cover one or both electrodes. This
way the discharge current is self-limited, and the discharge is
inhibited from turning into a spark. On the other hand, using
fast rise time short pulses allows the energy to be exclusively
coupled to the electron population and in this way, the gas
temperature remains relatively low. Pulses shorter than the
glow-to-arc transition time are an ideal solution to maintain
the nonequilibrium characteristic of a discharge.
3
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Figure 1. Schematic depiction of low temperature plasma (plasma jet) interacting with biological targets. Cells are typically covered by
biological fluids, so the plasma first interacts with a liquid layer. Secondary and tertiary reaction by-products generated in the liquid then
interact with the biological cells.

Figure 2. DBD with various configurations and electrode geometry.

Nonequilibrium, low temperature plasma offers a unique
medium that can be used to interact with biotic matter to selectively induce certain biological outcomes. The effects of CAP
on biological cells are mainly mediated by its ROS and RNS
(see section 4.1) [1].
In plasma medicine two types of low temperature plasma
sources have been extensively used, the dielectric barrier discharge (DBD) and the nonequilibrium atmospheric pressure
plasma jets (N-APPJ). The following are brief descriptions of
these two sources.

2.1.1. The dielectric barrier discharge. One of the earliest

methods to generate CAPs is to cover planar or cylindrical
electrodes by a dielectric material. The electrodes are separated by a small gap where the operating gas is introduced. The
electrodes are driven by voltages of several kV at frequencies
in the kHz range. This electrode scheme allowed the generation of stable discharges that can be filamentary or diffuse
depending on parameters such as frequency, voltage amplitude
and gas mixture. Common dielectric materials used in DBDs
include glass, quartz, ceramics and polymers. The gap distance
4
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discharge (or ‘primary’ discharge), was ignited at the rising
edge of the applied voltage pulse while the second discharge
(or ‘secondary’ discharge), was self-ignited during the falling
edge of the applied voltage pulse.
2.1.2. Nonequilibrium atmospheric plasma jets. N-APPJs are

devices that can emit low temperature plasma plumes in the
surrounding air. These plasma sources can generate a stable
thin column of plasma outside the confinement of electrodes
and into the surrounding environment. Because the plasma
propagates away from the high voltage region and into a region
where there is no externally applied electric field the plasma is
electrically safe in the sense that it does not cause electrical
shock to the treated biological targets. However, the plasma
plume may exhibit a very high instantaneous local electric field
at its tip.
N-APPJs come in various designs and geometries [29].
Investigators have used DC, pulsed DC, RF, and microwave
power to drive these plasma jets. Noble gases (such as helium
and argon) and gas mixtures (such as He/air, Ar/air, He/O2 ,
Ar/O2 , etc) are typically made to flow through at gas flow
rates in the 1–10 slm range. Figure 4 shows schematics of a
few examples of N-APPJs while figure 5 shows photographs
of four different plasma jets.
Investigators discovered that the plasma plumes emitted by
N-APPJs are not continuous but are in fact discrete plasma
segments that are known as ‘plasma bullets’. These plasma
bullets propagate at hypersonic velocities, up to 105 m s−1
[30, 31]. Extensive experimental and modeling studies resulted
in a good understanding of the physical mechanisms behind
the generation and propagation of the plasma bullets [32–43].
Lu and Laroussi first proposed a photoionization model to
explain the dynamics of the plasma bullets [31]. Further studies showed that the plasma bullets are in fact ionization waves
which are guided by the gas channel, hence the name ‘guided
ionization waves’ [44]. The electrical field at the head of the
ionization waves plays a crucial role in the propagation process and was experimentally measured by various investigators to be in the 10–30 kV cm−1 range [45–47]. Figure 6
shows a simulation of the electric field generated at the head
of the plasma plume as a function of axial position and time.
To learn more about N-APPJs the reader can consult reviews
[29, 48–50].
Readers who are interested in learning the basic physical
laws that govern low temperature plasmas can find a thorough coverage in the foundation paper [51]. This includes
discharge ignition, gas breakdown, Paschen law, diffusion,
scaling laws, sheath dynamic, streamer mechanisms, etc. In
addition, the fundamental concepts behind atmospheric pressure nonequilibrium plasma, which are of great relevance to
the plasma sources used in plasma medicine, can be found
in the foundation paper [52]. These include scaling laws,
timescales, discharge inception and breakdown mechanisms,
plasma instabilities, stabilization methods, etc [52].

Figure 3. Images of a DBD-generated filamentary plasma (a) and

that of diffuse DBD plasma (b). Images (a) and (b) are by Mounir
Laroussi.

between electrodes varies from less than 0.1 mm in plasma
displays, to several millimeters in ozone generators and up to
several centimeters in CO2 lasers. DBD devices can be made
in many different geometries, including planar and cylindrical. Figure 2 shows the schematic of different types of DBD,
including volumetric and surface discharges. Figure 3 shows
images of a filamentary DBD and a diffuse DBD plasma.
The arrangement of electrodes is generally contained within
a vessel to allow for the introduction of a defined gaseous mixture. When the discharge is ignited electric charges accumulate
on the dielectric surface. These surface charges cause a drop in
the voltage across the gas gap and a sharp decrease of the discharge current. In the filamentary regime, the discharge current
exhibits multiple erratic current spikes per half cycle. However, when the discharge is diffuse the current exhibits only a
few current peaks or ‘humps’ per half cycle being in phase with
the high voltage. Massines et al proposed a Townsend-type
breakdown or a glow discharge, depending on the gas used,
supported by seed electrons as well as surface memory processes (secondary electron emission by metastable molecule
impact) [23]. For more in-depth coverage of the DBD the
reader can consult reviews [24–27].
The electron energy distribution function (EEDF) plays a
crucial role in nonequilibrium discharges. It is through electron impact excitation and ionization that the charged particles,
excited species, and radicals are produced. Therefore, by tailoring the EEDF the plasma chemistry can be controlled to
a certain extent. One method to achieve such control of the
EEDF was to use repetitive short high voltage pulses. These
applied pulses allow for the transfer of power exclusively to
the electron population. This translates to enhanced excitation
and ionization. In addition, pulses with widths of less than the
characteristic time of the onset of the glow-to-arc transition
help keep the plasma stable and inhibits it from turning into
a spark. Investigators reported that for pulsed DBDs two discharges occur for every applied voltage pulse [28]. The first

2.2. Plasma reactive species

DBDs and N-APPJs produce a ‘cocktail’ of chemically
reactive species in the gaseous phase including ROS such
5
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Figure 4. Schematics of four N-APPJs with different electrode configurations.

Figure 5. Photographs of N-APPJs. (a) The plasma pencil driven by pulsed DC (image by ODU/M. Laroussi); (b) the kINPen driven by RF

power (image by INP/Th. von Woedtke); (c) Plasma jet driven by DC. Reproduced with permission from A. Shashurin; (d) Plasma jet driven
by a piezoelectric transformer. Reproduced with permission from C. Tendero.

As illustrative examples of CAP-produced reactive species,
figure 7 through figure 9 show two important species generated by plasma jets. Figure 7 shows the radial distribution
of hydroxyl, OH, for different gas flow rates while figure 8
shows the OH distribution in the presence of a target material.
Figure 7 illustrates the major influence of the gas flow rate and
indicates that the maximum OH density is close to the center
of the plasma plume and decays with radial distance. As can
be seen in figure 8, the presence of a target influences greatly
the production of OH. This highlights the fact that the type of
target has a dramatic influence on the OH concentration and
its radial distribution, with the maximum density at the center
followed by nearly exponential radial decay. A target with a
dry surface leads to lower OH production while a wet surface
results in a substantial increase in OH density. However, it is

as hydroxyl, OH, atomic oxygen, O, singlet delta oxygen,
O2 (1 Δ), superoxide, O2 − , ozone, O3 , and hydrogen peroxide,
H2 O2 . RNS such as nitric oxide, NO, and nitrogen dioxide,
NO2 , are also generated. When interacting with liquids other
secondary and tertiary species such as nitrite, NO2 − , nitrate,
NO3 − , peroxynitrite, ONOO− , peroxynitrous acid, ONOOH,
organic radicals, RO, are also generated. Detailed discussion of the reactive species generated in liquids under CAP
exposure will be presented in section 3 of this paper. As mentioned earlier, the concentrations and fluxes of these species
play crucial roles when CAP interacts with biological matter. Therefore, determining these concentrations qualitatively
and quantitatively is of paramount importance. The following provide some examples of these measurements and briefly
describe the diagnostics methods used to obtain them.
6
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Figure 6. Profile of the electric field at the head of the plasma

plume (outside of the plasma core area) of a pulsed plasma jet at
various times and axial positions. Reproduced from [37]. © IOP
Publishing Ltd. All rights reserved.

Figure 8. OH density radial distribution on wet/dry/rat skin surfaces

measured using LIF. Reproduced from [54]. © IOP Publishing Ltd.
All rights reserved.

Figure 7. Radial distribution of the OH density for various gas flow

rates measured using laser-induced fluorescence (LIF) (gas: helium
with 115 ppm of H2 O). The plasma jet has an insulated single pin
electrode inside a quartz tube and the plasma plume is applied on
top of a water film. © [2016] IEEE. Reprinted, with permission,
from [53].

Figure 9. Axial profiles of NO concentration for different RF

discharge power measured using LIF. The plasma is operated at a
frequency of 13.6 MHz, pulsed at 20 kHz with 20% duty cycle.
Working gas is Ar at 1 L min−1 with 2% air admixture. Reproduced
from [55]. © IOP Publishing Ltd. All rights reserved.

important to keep in mind that the concentrations of species
produced by plasma jets also depend on several other factors
including the humidity level of the surrounding environment,
gas flow rate, air mole fraction, etc. Figure 9 shows the axial
distribution of nitric oxide, NO, generated by an RF jet at
different applied powers, NO being a very important biological molecule. Figure 9 shows that the production of NO is a
function of the power applied to the plasma and that its density
decays rapidly with the axial distance away from the nozzle of
the device.
Finally, figure 10 shows the concentrations of various
species of biological relevance produced in the plasma plume

of an argon N-APPJ source as a function of the axial position.
As can be observed in the figure, some important species such
as O, NO, NO2 , O2 − , O3 , OH, H2 O2 , and HNO2 remain at relatively high concentrations in the far effluent, at up to a few
centimeters from the nozzle. Other species, however, are more
prevalent within a short distance from the nozzle and decay to
markedly low levels in the far effluent. Knowing these distributions helps inform the user which species are most likely to
play a role and at which locations.
7
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Figure 10. Axial concentrations of biomedically active species in an Ar plasma jet. Results are obtained from modeling. Reproduced from
[56]. © IOP Publishing Ltd. All rights reserved.

Figure 11. LIF setup to measure the concentration of OH. © [2016] IEEE. Reprinted, with permission, from [53].

To conclude this section, it is important to reiterate the fact
that quantitative evaluation of the type of species, their concentrations and their axial and radial distributions is crucial
for biomedical applications since the biological outcomes correlate directly with the fluxes of such species. To maximize
a flux of certain species could lead to distress and cell death
while a low flux of the same species could lead to eustress and
cell proliferation (see section 4 of this paper).

exhibit nonuniformities, invasive techniques (such as electrical probes) are usually not suitable. Optical diagnostics are
therefore preferred since they are mostly noninvasive and can
yield measurements that are resolved in time and in space.
These diagnostics techniques include optical emission spectroscopy (OES), optical absorption spectroscopy, laser induced
fluorescence (LIF), and two photon absorption laser induced
fluorescence (TALIF). In addition, scattering techniques such
as Thomson, Rayleigh, and Raman scattering can be used.
Other advanced spectroscopic methods such as cavity ring
down spectroscopy have also been used to evaluate very low
concentrations of some species [57]. Finally, well-established
chemical analysis techniques including mass spectrometry and
electron paramagnetic resonance (EPR) spectroscopy are at the
investigators’ disposal. In the following section, only a brief

2.3. Diagnostics methods for low temperature plasmas

In addition to well-established electrical characterization (to
measure current, voltage, power) there are several diagnostics
methods to identify and measure the concentrations of reactive species produced by low temperature plasmas. Because
typically CAP sources have relatively small dimensions and
8
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Figure 12. Indirect treatment: first, a liquid solution is exposed to LTP (top photograph), then the treated solution is applied on top of the
cell (bottom schematic).

Table 3. Fraction of important bond dissociations and associated standard deviations upon impact of O, O3 ,
OH, and H2 O2 a . Reproduced with permission from [62], Copyright (2013) American Chemical Society.

Incident plasma
species

C–N bond
breaking events (%)

Ether C–O bond
breaking events (%)

C–C bond
breaking events (%)

O atoms
O3 molecules
OH radicals
H2 O2 molecules

26 ± 6
8±4
8±4
0

78 ± 6
56 ± 7
54 ± 7
44 ± 7

38 ± 7
26 ± 6
14 ± 5
12 ± 5

a

Note that the values are calculated from 50 independent simulations for each incident species.

coverage of OES, LIF, and TALIF diagnostic techniques is presented. For more in-depth information on optical diagnostics
methods the reader can consult the review papers [58, 59].
OES is a relatively simple technique that can yield both
qualitative and quantitative measurements. OES is used to
identify excited species and absolute OES can measure
their absolute densities but requires careful calibration. Only
excited species that emit radiation can be identified and/or
measured by OES. Species in the ground state cannot be
detected by OES, so they require other measurements methods such as LIF and TALIF. OES has been used to measure the gas temperature, electrons density, and electric field
strength. The gas temperature is deduced from the rotational
temperature in the case of molecular gases. For example, the
rotational structure of the 0–0 band of the second positive system of nitrogen is often used to estimate the gas temperature.
This is done by comparing experimental data with simulation data. The electron density can be found using the Stark
broadening by exploring the Balmer transition Hβ of hydrogen

at 486.132 nm. However, this broadening is usually resolved
only when the electron density is greater than 1013 cm−3. OES
can be used to measure the electric field strength by applying
the polarization-dependent Stark splitting and shifting of the
helium 447.1 nm line and its forbidden counterpart. To learn
the details of the above mentioned OES techniques the reader
can consult reference [59].
LIF allows us to measure species in the ground state. LIF is
based on a two-step process. First, a photon is absorbed by an
atom or molecule. As a result, the absorbing particle is excited
to a higher energy state. The excited species then undergoes
spontaneous radiative decay to a lower energy level and in the
process releasing a photon at a different wavelength than that
of the incident laser light. The emitted photons constitute the
fluorescent light signal, which can be detected, and its intensity measured. Figure 11 shows an example of an LIF setup to
measure the concentration of OH produced by a plasma jet. By
calibration or via signal fitting process the concentration of the
species can be deduced. LIF can be used to measure atomic or
9
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Figure 13. Main processes involved in the plasma–liquid interaction. The species represent the case of an Ar/air plasma interacting with
water. Reproduced from [69]© IOP Publishing Ltd. All rights reserved.

molecular species, however, it is more complex for molecules.
This is because vibrational and rotational energy transfers can
influence the radiative decay. Reference [60] presents a good
example of how LIF can be applied for nonequilibrium plasma.
In TALIF the probed species is first excited by a photon
to an intermediate state. The intermediate level can be a virtual state or a real electronic state. A second photon excites the
species into a final higher state and then after radiation decay to
a lower state a fluorescence signal is emitted. As an example,
TALIF has been used to measure the concentrations of atomic
oxygen. In this case, a laser beam at a wavelength of 225.62 nm
is used to excite atomic oxygen from the 2p4 3 P2 state to the
3p3 3 P2 state. The fluorescence signal is captured at a wavelength of 845 nm, which corresponds to the transition from
3p3 3 P2 state to the 2s3 S state of O. The absolute concentration can be estimated by calibration methods. For more details,
the reader can consult reference [58].
The above section discussed only measurements methods
to evaluate concentrations of relevant species in the gaseous
phase, generated by plasma. Section 3 of this paper discusses
the methods used to measure concentrations of species
generated in the liquid phase. There are well-established
techniques, molecular probes, and assays to carry out
such measurements. These include spectrophotometric assays (such as Griess assay for measuring nitrate),
cholorimetric/fluorometric assays (such as Amplex red assay
for measuring hydrogen peroxide), singlet delta oxygen
sensor, chemical titration (for ozone), etc.

In the case of sterilization/decontamination, the plasma can
either come in direct contact with the cells (bacteria, viruses,
fungi, biofilm, etc) or the cells can be placed in a location
where they are exposed only to the plasma effluent or, in specific cases, to plasma processed air (indirect treatment). In
direct treatment all the possible plasma-produced agents act
on the cells. These include charged particles, reactive species,
photons, electric field, and heat. In indirect treatment the
contribution of charged and electronically excited particles,
electric field, heat, and photons are greatly reduced or even
eliminated. In this case, mostly the long-lived species generated by the plasma reach the biological target.
In the case of CAP treatment intended for medical therapies such as wound healing or cancer treatment, direct and
indirect treatments take different meanings. Direct treatment
can mean that the plasma or the plasma afterglow touches
the target. Indirect treatment often means that CAP is first
used to treat a liquid solution and then the plasma-treated
solution is applied on top of cells, wounds, or injected into
tumors. The used solutions include saline solution, cell culture
media, ringer’s lactate solution, etc. In this treatment modality the effects of heat, photons, and electric field are eliminated. In addition, under specific conditions plasma-treated
solutions (PTS) can be stored and used at a later time (h day−1 ).
Figure 12 illustrates the steps involved in such treatment
modality.

2.5. Modeling of CAP-cell and CAP-tissue interactions
2.4. Methods of treatment

This section briefly describes the computer models that have
been used to simulate the interaction of CAP with biological
matter. For extensive descriptions of the computer simulations

In plasma medicine the biological targets (cells, tissues,
organs, etc) can be exposed to CAP in a direct or indirect way.
10
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Figure 14. Effect of liquid evaporation on the gas-phase
concentration of hydroxyl radicals. Reproduced from [72]. © IOP
Publishing Ltd. All rights reserved.

Figure 16. pH and conductivity variation during the air plasma
treatment of DIW (green triangles), electrolyte solution (red
diamonds) and phosphate buffered solution (blue circles). Reprinted
from [74], Copyright (2015), with permission from Elsevier.

Figure 15. Gas-phase and liquid-phase concentration of hydrogen
peroxide for different humidity concentrations. Reproduced from
[73]. © IOP Publishing Ltd. All rights reserved.

used to model low temperature plasmas, the reader is referred
the foundation paper by Alves et al [61].
A few researchers have attempted to model the interactions of low temperature plasma with biological cells and tissues. So far, two types of simulations approaches have been
used, molecular dynamics (MD) simulations and hydrodynamic simulations. MD simulation (both classical MD and ab
initio MD) is a method that allows the system to be described
on the atomic level while hydrodynamic simulation is used on
a more macroscopic level to describe the system on the cellular/tissue level. In the latter simulation method, the cells and
tissues are modeled by dielectric materials having certain permittivity and conductivity. Using the above-mentioned methods, simulations of plasma interactions with bacteria, with
eukaryotic/mammalian cells, and with tissues have been carried out [62, 63]. For example, MD simulations have been
used to study the plasma effects on DNA, peptidoglycan, lipid
bilayer, ion transport, and electroporation. These simulation
studies are very important as they can shed light on phenomena on the atomic, molecular, subcellular, and cellular levels
and can yield useful data that are hard or even impossible to
obtain experimentally. The following are a few examples of
what has been uncovered using such computer simulations.

Figure 17. Evolution of the concentration of reactive species in DIW

after air plasma treatments of 5 or 10 min (filled and empty symbols,
respectively); green squares refer to H2 O2 and blue circles to NO2 − ,
the conjugate base of nitrous acid. Reprinted from [74], Copyright
(2015), with permission from Elsevier.

To elucidate the effects of CAP on bacteria on fundamental and molecular levels, Yusupov et al conducted computer
simulations on the interaction of ROS with bacterial peptidoglycan, which is a major constituent of the bacteria cell wall
[62]. For this, they used reactive MD simulations and they
found that ROS affect the structure of peptidoglycan by breaking the C–N, C–O, and C–C bonds. Table 3 shows the percentage of breaking events of the C–N, C–O, and C–C bonds
and which plasma species is responsible for the breakage [62].
Note that, for example, hydrogen peroxide, H2 O2 , was found
to be responsible for breaking the C–O and C–C bonds, which
indicate that H2 O2 specifically affects the disaccharide part of
11
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Figure 18. Schematic representation of the most important diffusion processes and chemical reactions taking place at the interface and in
the bulk of plasma treated DIW. Reproduced from [82]. CC BY 4.0.

chemistry dominated by ROS. With their model, they were also
able to assess the thermal and electrical safety of CAP devices
used on living tissue [64].
MD simulations have been used to study the electropermeabilization of cell membranes, ion transport through
electropores, reactive species interaction with cell membranes
and with biomolecular structures, lipid peroxidation, and interaction of reactive species with liquids. Detailed coverage of the
computational methods and the results obtained in relation to
these interactions can be found in reference [63].
Babaeva and Kushner carried out hydrodynamic simulations to study the propagation of electric field, plasma filaments through tissue, and fluxes of reactive species on
tissues [65–67]. They used a 2D plasma hydrodynamic
nonPDPSIM to study the propagation of streamers, the production of reactive and charged species as well as their fluxes
on tissues and wounds. Using this model, they also investigated
electroporation and the propagation of electric fields through
skin and wounds. They found that the curvature of the skin
influences greatly the propagation of the plasma filaments.
As the filaments reach the skin surface, charge accumulation
occurs resulting in the production of a lateral electric field that
spreads the filaments over the surface of the wound. In addition, significant electric field penetration into the intracellular
structure can occur to establish a high enough field for electroporation to occur. These investigators also quantified the
fluxes of ROS and RNS, ions and photons towards the wound.
They found that for typical DBD operating conditions, both
the ROS and RNS show fluences over a treatment time of a
few seconds comparable to those on the surface [65–67]. The
same investigators also reported on the interaction of ROS and

Figure 19. Evolution of the liquid phase concentration of H2 O2 ,
NO2 − and NO3 − after plasma treatment (pH 3.3). Reproduced from
[84]. © IOP Publishing Ltd. All rights reserved.

the peptidoglycan. For a detailed description of the computational method used and all the simulation results, the reader is
referred to reference [62].
Chen et al developed a molecular simulation of plasma
chemistry that can link to functions on the cell and tissue levels [64]. In the case of biofilms, a reactive penetration model
was used for mass transfer of transient plasma reactive species
across the gas–liquid boundary. In the case of tissue, they used
a fluid model and equations of heat and electric field transfer
through the skin. Their results revealed that the penetration of
plasma chemistry into hydrated biofilms is 10–20 μm deep,
which correlated with the penetration of liquid-phase plasma
12
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RNS with liquid-covered wounds and showed that alkane-like
hydrocarbons in the liquid influences which species reach the
wound.

deionized water (DIW), a phosphate buffered solution and an
electrolyte solution [74].
Referring to the liquid-phase chemical species, a distinction i made between short-living and long-living species; the
first term is used to refer to highly reactive species with a short
lifetime, mainly involved in chemical reactions at the interface,
while the second term refers to more stable species, populating the bulk of the liquid. In the field of plasma medicine,
this distinction is often made on practical terms. Long-living
species refer to those having a lifetime long enough to survive in the liquid for a certain amount of time after the plasma
treatment, enabling indirect treatments. H2 O2 and nitrous acid,
HNO2 , are among the long living species always encountered
after plasma treatment of aqueous solutions in the presence
of air and humidity in the gas phase, as shown in figure 17
[74]. Short-living species, on the opposite, should play a role
only in direct treatments. Although very practical, these definitions fail to account that many long-living species, over their
lifetime, undergo chemical reactions, locally releasing highly
reactive short-living species that can thus exert biological
effects also in the case of indirect treatments.
The apparently straightforward figure 17 evidences the
complexity of the liquid chemistry initiated by the plasma
treatment and the interdependence of many factors. As an
example, the fact that longer treatment times induce higher
concentrations of H2 O2 and nitrates (NO2 − ) in DIW, but also
their faster degradation once the plasma treatment is over, can
only be explained by a concurrent reduction of the solution
pH, induced by the treatment itself and influencing the various
reaction taking place in the liquid during and after the exposure
to the discharge.
The aim of this chapter is to introduce the reader to the processes taking place in the gas–liquid interface and in the liquid
phase. After describing the chemistry initiated by plasma in
pure water, the case of liquids of more complex composition
will be considered and techniques for the study of the effects
induced by plasma in liquids will be introduced.

3. Plasma-induced effects in liquids
and at bio-interfaces
The biological effects induced by plasma treatment revolve
around the interaction of plasmas with a liquid. This aspect
is almost obvious if we consider the case in which plasma is
used to treat a liquid, which is then applied to exert a certain biological effect (indirect treatment). Nonetheless, even
when the biological target is directly exposed to the plasma
(direct treatment), liquids act as mediator of plasma effects
since, under physiological conditions, a liquid environment
surrounds cells and tissues. This liquid layer is typically a few
hundred micrometers thick and its composition depends on the
specific cells/tissue considered; as an example, the composition of the liquid layer in early-stage wounds is composed of
93% water and 7% proteins [68].
The main processes involved in the plasma–liquid interaction are shown in figure 13, where the reported species are
those typically encountered in the case of an Ar/air plasma
interacting with water. The schematic highlights the existence
of an interface separating the plasma and bulk liquid region,
where a number of key processes take place.
Over the course of the treatment, plasma components such
as electrons, photons, radicals and gas-phase ROS and RNS
penetrate the interface, diffusing and triggering chemical reactions with the formation of liquid-phase chemical species.
These species can then diffuse out of the interface and reach
the bulk liquid, where further chemical reactions take place.
Liquid evaporation and sputtering at the interface add another
layer of complexity, since these processes alter the gas-phase
composition and, as a consequence, the type and concentration of plasma components flowing towards the liquid. The
feedback effect of the liquid on the gas-phase chemistry is
highlighted in figure 14, where modeling results for the case
of an air plasma show that the gas-phase concentration of
hydroxyl radicals (OH) is severely enhanced when evaporation
takes place [70]. The interdependence of gas-phase chemistry
and liquid-phase chemistry is further highlighted in figure 15,
focusing on hydrogen peroxide (H2 O2 ). The reported experimental results demonstrate that the humidity concentration
influences the concentration of gas-phase H2 O2 , which in turn
influences the liquid-phase concentration of H2 O2 [71].
The liquid-phase chemistry certainly depends on the type
and concentrations of the gas-phase species penetrating the
interface, but also on the characteristics of the liquid itself. As
an example, the Henry’s constant (see table 1), indicating the
liquid-phase concentration of a species having a certain partial pressure in gas-phase, is a function of both the diffusing
species and the liquid. Also, liquid composition, conductivity
and pH strongly affect the chemical reactions taking place in
the aqueous phase. Interestingly, depending on the composition of the liquid, its conductivity and pH may vary over the
course of the treatment, as shown in figure 16 for the case of

3.1. Plasma-induced chemistry in deionized water

This paragraph deals with the general aspects of plasmainduced liquid chemistry and with the reactions taking place
in pure water, namely water without any organic or inorganic
impurities. Experimentally, DIW is often used as a representative system for pure water, but a few clarifications are needed.
As the term suggests, in DIW ions have been removed, resulting in a highly pure water with negligible conductivity and, at
least immediately after its production, neutral pH. DIW exposure to air leads to the absorption of oxygen (O2 ) and carbon
dioxide, CO2 ; the latter is responsible for the formation of carbonic acid, H2 CO3 , and the reduction of DIW pH below 7.
These processes are worth mentioning since in most plasmamedical applications, the liquid is exposed to air before the
plasma treatment. Another difference of DIW compared to distilled water is that the chemical process for its production does
not alter uncharged and organic contaminants. It should be
noted that, even if not perfectly representative of pure water,
13
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Figure 20. Concentration of chemical species in plasma-treated DIW with (blue) and without (red) biomolecules in the liquid. Reproduced

from [83]. © IOP Publishing Ltd. All rights reserved.

Figure 21. Schematic of the concept of plasma medicine as applied redox biology following the concept of oxidative eustress and distress
inaugurated by [116]. Reproduced with permission from [111].

Chemical reactions induced by plasma treatment of water
can be classified into four categories: (i) acid–base reactions;
(ii) oxidation reactions; (iii) reduction reactions; (iv) photochemical reactions [71]. Acid–base reactions are associated
with the release of hydrogen ions, H+ , in water and are responsible for the change of the pH of the solution, which is a
parameter with a direct influence on the liquid conductivity
and on several chemical reactions happening in plasma treated

DIW is the liquid system with the greatest number of dedicated
studies available in the literature due to having a simple composition that guarantees reproducibility, limits the number of
chemical reactions taking place and facilitates its characterization. Computationally, on the other hand, water composition
can be more easily set to represent pure water or to account
for compositions that are more complex as in DIW, buffered
solution or even for the presence of amino acids.
14
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Figure 22. Major targets of CAP compounds on cellular structures with ROS and RNS (radicals and chemical products) as dominant active

compounds. Reprinted from [133], with the permission of AIP Publishing.

liquids [71, 75, 76]. Generally, most of the ROS and RNS produced in the plasma discharge display acid–base properties.
Which plasma species influence the liquid acidity the most
depends on the treatment setup and conditions. In the configuration typically encountered in plasma medicine applications,
which involves a plasma discharge in air or surrounded by air,
the treated DIW display an increase of acidity mainly due to
the formation of nitrous acid, HNO2 , and nitric acid, HNO3 , in
the liquid [77]. The presence of these acids is directly related to
their diffusion from the gas phase into the liquid phase, favored
by their high solubility in water [78]. Their formation in the
gas phase is attributed to the following reactions [79], where
nitrogen oxide, NO, hydroxyl radicals, OH, and ozone, O3 , are
chemical species characteristic of plasma discharges in presence of air and humidity (M is an additional partner, e.g. N2 ):
NOg + OHg + M → HNO2g + M

(1)

NOg + O3g → NO2g + O2g

(2)

NO2g + OHg + M → HNO3g + M.

(3)

Strong acids, such as nitric acid, are completely dissociated
in the solution. On the other hand, the dissociation of weak
acids, such as nitrous acid, depends on their acid dissociation
constant (Ka ) and on the pH of the solution. More specifically, the pKa (defined as −log(Ka )) of the acid represents the
approximate value of pH of the solution above which the acid
is mostly dissociated.
Oxidation reactions are associated with the presence of oxidizing species in the liquid, either diffused from the gas phase
or directly formed in the liquid phase. In the context of plasmamedical applications, oxidizing species serve a dual role of (i)
participating in the chemical reactions that define the chemical
composition of the liquid, and (ii) directly interact with the biological cells and tissues to be treated. For the case of a plasma
in air, the key oxidizing species are OH radicals, H2 O2 , O3 , and
peroxynitrous acid, ONOOH, with its conjugate base peroxynitrite, ONOO− . Of these species, O3 is formed in gas phase
and diffuse in the liquid, while ONOOH is formed directly in
liquid phase; OH radicals and H2 O2 presence in the liquid is
due to both diffusion after formation in gas phase and direct
formation in liquid phase [82, 83].
Similar to oxidation reactions, reduction reactions are
linked with the presence of reducing species in the liquid. The
superoxide radical, O2 − , formed either by the hydrolysis of
perhydroxyl radicals, HO2 , or by solvated electrons [83], is
particularly relevant in plasma medicine applications due to
its participation in reactions resulting in the production of peroxynitric acid, O2 NOOH and peroxynitrous acid, ONOOH,

Once in the liquid phase, nitric and nitrous acid are
hydrolyzed as per the following reactions, leading to a
decrease of pH of DIW [80, 81]:
HNO2aq → H3 O+ aq + NO−
2aq

(4)

HNO3 aq → H3 O+ aq + NO−
3aq .

(5)
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which are considered among the responsible for the biological
effects observed for plasma treated DIW [84, 85].
The last class of reactions are driven by plasma-produced
UV radiation that penetrates the liquid and induces photochemical reactions. These reactions often result in the production of OH radicals, which have been previously mentioned as
strong oxidizers. H2 O2 photolysis can be taken as an example
[86]:
(6)
H2 O2aq + hν → 2OHaq .

concentration in liquid phase is dissociated in OH radicals by
photons (reaction 6) or solvated electrons (reaction 7) and can
take part in the following reaction that results in the production
of HO2 :
H2 O2aq + OHaq → HO2aq + H2 Oaq .

While reactions 6 and 7 can take place only at the interface,
reaction 10 is relevant also in the bulk of the liquid, where the
presence of H2 O2 is guaranteed by its lifetime and enabled by
mass transport. As a final note, it was experimentally demonstrated that the H2 O2 found in liquid phase after plasma treatment is mostly produced in gas phase [73, 87]. Besides its
high solubility (indicated by a high Henry’s law coefficient,
see table 1) parameters like the gas–liquid interface surface
area, the gas flow rate as well as the treatment time are relevant for the H2 O2 transport into the liquid phase so that its
concentration is mainly determined by its depletion from the
gas phase [88].
Another gas phase species acting as chemistry initiator once
diffusing into the liquid is HNO2 , which partially hydrolyzes
with the formation of its conjugate base NO2 − and triggers
the following chemical reactions resulting in the production of
ONOOH and O2 NOOH:

It should also be noticed that, in the case of direct treatments, the part of UV radiation not absorbed by water can
directly react with the biological tissue.
Moving beyond the general classification of the reactions
that can take place in the plasma-treated liquid, many experimental and computational studies have shed light on the most
relevant reactions and on the spatial-temporal distribution of
the chemical species in the liquid phase [70, 82, 83]. Liquid phase chemistry is initiated by plasma produced species
that diffuse from the gas phase. This process is dominated by
the concentration of said species and by their Henry’s constant (see table 1). As a further specification, the concentration
of these gas phase species depends on many factors, among
which type of plasma source is used, the type of electrical excitation, the composition of the gas phase and the duration of
the plasma treatment, since the concentration of long living
species such as O3 and HNO3 increases over time. The behavior of each aqueous species is then determined by diffusion
and competitive production–destruction mechanisms, whose
relative importance depends on the dissolution depth, meaning that the reactions at the gas–liquid interface differ from
those taking place in the bulk liquid [82].
Of the species diffusing into the liquid, positive ions only
influence the pH of the solution by charge exchange with water
molecules; charged water molecules, H2 O+ , then form hydronium ions, H3 O+ , upon reacting with other water molecules,
decreasing DIW pH [83]. On the other hand, electrons diffusing into the liquid rapidly solvate and lead to the formation of
OH and O2 − according to the following reactions:
e + H2 O2aq → OHaq + OH− aq

(7)

e + H2 Oaq → H2 O− aq

(8)

H2 O− aq + O2aq → H2 Oaq + O−
2aq .

(9)

(10)

HNO2aq + OHaq → H2 Oaq + NO2aq

(11)

−
NO−
2aq + OHaq → OH aq + NO2aq

(12)

NO2aq + OHaq ↔ ONOOHaq

(13)

NO2aq + HO2aq ↔ O2 NOOHaq .

(14)

Reactions 11, 12 and 13 require the presence of OH radicals, whose concentration at the interface depends on OH diffusing from the gas phase (75%) and H2 O2 dissociation (25%),
as per reactions 6 and 7 [83]. Due to their chemical reactivity,
OH radicals are rapidly depleted and concentrations smaller
than 1 nM are found below 1 μm from the interface [82].
Nonetheless, OH radicals participate in chemical reactions
also in the bulk of the liquid, where they are released by the
dissociation of ONOOH (the reverse of reaction 13, favored
under acidic conditions), acting as donor for OH. Since the liquid bulk is lacking the main source of OH radicals present at
the interface (diffusion from the gas phase), OH concentration
in the bulk becomes negligible because the locally formed OH
react and are depleted over timescales as short as microseconds
[89]. Peroxynitric and peroxynitrous acids diffusing from the
interface are also the source of NO2 radicals in the bulk of the
liquid.
To conclude the overview of the most important ROS and
RNS found in plasma-treated DIW, ozone is a species with
a very high oxidation potential that can diffuse from the gas
phase into the liquid phase. Its concentration in the liquid
phase depends mainly on its gas phase concentrations, thus
on the operating and environmental conditions of the plasma
treatment. Depending on its concentration, O3 can diffuse outside the interface, reaching the bulk of the liquid. Even if not
directly related to the case of plasma-treated DIW, it must be

Among the neutrals diffusing into the liquid phase, HNO3
shows a peculiar behavior since it only affects the solution pH
by releasing hydrogen ions (reaction 5). Since neither HNO3
nor its conjugate base take part in other chemical reactions,
nitric acid is not an initiator of the chemistry of plasma treated
liquids. It is nonetheless an extremely important species since
the solution pH determines acid–base reactions for weak acids
such as HNO2 , ONOOH and O2 NOOH. As a further implication of its chemical stability, HNO3 concentration at different
depths depends mostly on mass transport.
More often, neutrals diffusing from the gas phase behave as
initiators of liquid chemistry. As a first example, upon diffusing into the liquid H2 O2 , typically the ROS with the highest
16
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Figure 23. Discussed mechanisms of plasma-caused tissue effects; Reproduced from [134]. CC BY 4.0.

mentioned that in liquids with neutral or basic pH, O3 in liquid
can initiate a set of reactions resulting in the formation of OH
radicals [90].
Most of the processes here described are graphically represented in figure 18; continuous and dotted lines represent relevant and negligible reaction pathways, respectively; hollow
arrows indicate which species can diffuse from the interface to
the bulk of the liquid.
As previously mentioned, chemical reactions continue to
take place in the liquid even after the plasma treatment and
depend on the pH of the solution. While species such as H2 O2 ,
NO2 − , NO3 − and O3 can be measured in the DIW hours after
the plasma treatment, their concentrations evolve over time.
This is shown in figure 19 where data refer to a solution with
pH 3.3 [84]; peroxynitric and peroxynitrous acids also can be
found in the treated water for a substantial amount of time after
the plasma treatment [84, 85, 91, 92].
These long living species are responsible for the release of
highly reactive short living species in the liquid, such as the
radicals OH, O2 − and NO2 , ensuring their presence in the liquid even once the plasma treatment is over. In principle, these
processes are similar to those happening in the bulk of the liquid and described by the reverse of reactions 13 and 14; HO2
radicals produced by O2 NOOH decomposition can hydrolyze,
with the production of O2 − radicals:
HO2aq → H3 O+ aq + O−
2aq .

The temperature of the liquid is another parameter influencing post discharge reactions, as shown for the case of peroxynitric acid chemistry by Ikawa et al [85], who indirectly
demonstrated that the lower is the conservation temperature
of the plasma treated liquid, the longer is the time extent over
which O2 − radicals are released. This aspect has obvious practical repercussions, potentially enabling to extend the functional lifetime of a plasma treated solution through freezing
and proper conservation.
For interested readers, a more detailed discussion of the
post-plasma treatment chemical reactions can be found, among
others, in [83–85].

3.2. Plasma-induced chemistry in complex liquids

The liquids encountered within the context of medical applications of plasmas are rarely, if ever, as simple as DIW. In
the case of indirect treatments, the choice of the liquid to
be treated is guided by reasons such as its biocompatibility
and compliancy with regulations. Examples of such reasoning can be found both in the treatment of cell culture media
in the context of fundamentals studies on the effect of plasma
treated liquids on cells and in the treatment of Ringer’s lactate
solution with the intent of a clinical application as anti-tumor
strategy [93–96]. In the case of direct treatments, biological
liquids such as blood and interstitial fluids have complex compositions, with the presence of biomolecules, particles and

(15)
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buffering species mixed in water. All these components participate in the ongoing chemistry of the plasma-treated liquid,
leading it astray from the simple DIW case, and pose significant challenges in the measurement of the reactive species
and in the identification of the leading reaction mechanisms.
Many groups have started venturing into this highly interdisciplinary field, defining important milestones while struggling
with experimental and modelling constraints.
Arguably, the largest number of studies dedicated to complex liquids focuses on the implications of the presence of
a buffer compound, a weak acid and its conjugate base, in
the treated solution. Once a strong acid or base is added,
buffer solutions resist the variation of pH since the equilibrium between the buffer acid and its base is shifted, limiting
the increase (in case of adding a strong acid) or decrease (in
case of adding a strong base) of hydrogen ions, H+ , in the
mixture. Referring to biological liquids, the pH of blood and
interstitial fluid is regulated by the bicarbonate buffer system,
whose components are carbonic acid, H2 CO3 , and bicarbonate
ions, HCO3 − , and by the phosphoric acid, H3 PO4 , buffer system; proteins (e.g. hemoglobin and albumin) also contribute
to maintain the blood pH in the range 7.35–7.45 [97, 98].
Experimental studies on this subject often involve the use of
phosphate buffered solutions, where the pH buffering derives
from sodium and potassium salts that, mixed in the liquid,
originate phosphoric acid and sodium hydroxide (a base). In
one of the most thorough articles on the subject [84], Lukes
et al clearly evidenced that the pH of the solution has a strong
impact on the concentration of species formed in the liquid
during the plasma treatment and on their evolution in the postdischarge period. With respect to an acidic solution, as could
be non-buffered DIW when plasma treated in presence of air,
solutions with a neutral pH, such as buffered DIW, result in
higher concentrations of H2 O2 and NO2 − . In addition, the concentration of these species was found to remain constant for
an extended amount of time in the case of a neutral solution,
while in acidic conditions they tend to decrease, as previously
shown in figure 19. Beside the concentration of long living
species, the pH also affects the chemical pathways taking place
in the solution. As an emblematic example, ONOOH exists in
its acid form (peroxynitrous acid) when the pH of the solution is below 6.8, while above that threshold it will be mostly
present in its dissociated form of peroxynitrite ion, ONOO− .
Both these species can participate in oxidative reactions, but
the character of ONOOH to donate OH radicals and NO2 , represented by the reverse of reaction 13, can only be observed
under acidic conditions.
The desire to investigate the treatment of liquids already in
use clinically have spurred the interest for Ringer’s lactate, a
mixture of L-sodium lactate, potassium chloride, KCl, sodium
chloride, NaCl, and calcium chloride, CaCl2 , in water. Compared to the treatment of DIW, the presence of L-sodium lactate in the solution was found to increase the concentration of
H2 O2 and to induce the formation of acetyl, CH3 CO, and pyruvic acid-like groups, CH3 COCOOH [96]. While this study
enabled the identification of which of the components of the
Ringer’s lactate is responsible for the anticancer properties of

the treated solution, detailed descriptions of the chemical composition of the liquid and of the chemical reactions triggered
by the plasma treatment are still unavailable.
As a final example, the effect of the presence of
biomolecules in the treated liquid was shown by Lietz and
Kushner [83] comparing the concentration of reactive species
in a treated liquid with or without the presence of peptydoglican. The highlight of their modelling study, reported in
figure 20, is that biomolecules can significantly deplete ROS
such as O3 and OH, with opposite impacts on the concentration of molecules that would be consumed by reactions with
those species (e.g. HO2 ) and others that would need those
species to be formed (e.g. ONOOH). The counterpart of this
loss of reactivity is the formation of biomolecules with broken bonds and radical sites that can trigger specific chemical pathways that were mentioned, but not covered, in the
paper.
3.3. Diagnostic methods and modelling tools
for the investigation of plasma-treated liquids

The previous paragraphs should have clarified that much
is known of the chemistry initiated in liquids after plasma
treatment, and that even more is still unknown. There are
many tools available to further explore this scientific field,
among which are colorimetric assays, chromatography and
EPR spectroscopy; these techniques have been explained in
detail elsewhere [70, 99, 100] and it is our intent to provide here only a brief introduction to a few of the available
instruments.
Probably the simplest method to assess the concentration of
long-living reactive species, such as H2 O2 , NO2 − and NO3 − ,
in the liquid is the use of test strips [74]. When immersed in
the liquid for a specified amount of time, test strips change
color depending on the concentration of the reactive species
they are calibrated for; the operator can thus perform a semiquantitative measurement comparing the color of the strip
against a calibrated chromatic scale provided by the strip manufacturer. However, it has to be kept in mind that test strips
might not have a sufficient selectivity as well as accuracy
because of cross-sensitivities to other species. Consequently,
in plasma-treated liquids that are complex cocktails of species,
a distinct identification or quantification of reactive species
could be problematic. Therefore, test strips should rather be
used for orienting investigations.
On the other hand, quantitative measurement can be
obtained using colorimetric assays, which rely on the change
of color induced in the solution by a known reaction. Practically, two main approaches are available: (i) dyeing the
solution with a compound known to selectively react with a
certain species and measuring the discoloring of the solution,
as in the case of O3 bleaching of blue indigo dye [101]; (ii)
adding a compound known to selectively react with a certain
species with the production of a colored chemical species, e.g.
the titanyl sulfate complex (yellow) formed by the reaction of
H2 O2 with titanium sulfate [102]. Depending on the specificities of the assay, these measurements are performed either with
a spectrophotometer or a spectrofluorometer.
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Figure 24. Cold physical plasma triggers nuclear translocation of Nrf2, and induces colocalization of Keap1 with actin filaments in the cyto-

plasm. (A) Dermal fibroblasts (bright field image, left) were isolated from SKH1 mouse skin and exposed to cold physical plasma-derived
ROS/RNS. Upon nuclear translocation of the nuclear factor erythroid 2-related factor 2 (Nrf2), plasma significantly altered antioxidant and
phase II detoxification enzymes and proteins (e.g., heme oxygenase 1 (HMOX-1), NADPH quinone oxidoreductase 1 (NQO1), thioredoxin
(TXN), glutathione reductase (GSR), superoxide dismutase (SOD), glutathione S-transferase (GST), glutathione (GSH) etc). (B) Cytoplasmic
localization of Kelch-like ECH-associated protein 1 (Keap1) was detected immunohistochemically by anti-Keap1 antibody (red). Colocalization of Keap1 with actin filaments was visualized by staining with fluorescein isothiocyanate (FITC)-phalloidin (green). (C) Subcellular
localization of Keap1 (green) and trans-localization of Nrf2 (red) from the cytoplasm to the nucleus were detected immunohistochemically
by anti-Keap1 and anti-Nrf2 antibodies in plasma-treated (right panel), but not control fibroblasts (left panel). Scale bars 100 μm (A), 50 μm
(B) and (C). Reproduced from [156]. CC BY 4.0.

measured quantitatively by EPR with the use of spin trapping
probes [104–107].
As a final note on the experimental methods, well established techniques relying on the use of standard electrode systems are available for those situations where it is sufficient to
measure the redox potential of the plasma treated liquid [108].
Modelling tools offer a complementary and interdependent approach to diagnostic techniques. Indeed, on the one
hand, modelling enables the investigation of aspects otherwise
impossible to study, such as the identification of the chemical
pathways taking place in a plasma-treated liquids; on the other

Chromatographic techniques rely on a controlled separation
of the components of the sample to be analyzed, which flows
through a stationary element; the components of the sample
that display different affinities for the material of the stationary element flow at different velocities, effectively becoming
separated before reaching a detector. In the context of characterizing plasma-treated liquids, ion chromatography has been
used to measure NO2 − and NO3 − [84] and liquid chromatography has enabled the measurement of short-living species, such
as OH and HO2 radicals, stabilized by using chemical probes
[103]. Similarly, short living radicals, e.g. OH and O2 − , can be
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hand, modelling requires input data, often provided experimentally, and experimental validation. Modelling the plasma
treatment of a liquid requires the coupling of three main components: (i) the gas phase model, accounting for plasma formation, plasma kinetics and fluid-dynamic aspects; (ii) the
liquid phase model, where transport processes and chemical
reactions are simulated; and (iii) the interface model, which
takes into account the transport of species from the gas phase
into the liquid phase and vice versa. A thorough introduction
to the modelling of the plasma treatment of liquids, covering the available approaches and the limitations to consider,
is provided in the 2016 plasma–liquid interactions roadmap
[70]. Other valuable insights to further approach and better understand the potential of this instrument can be found
in [61, 72, 82, 83].

The central role of redox processes in cell biology is
expressed by statements like ‘redox biology is at the heart of
life sciences’ [113], or ‘redox chemistry constitutes the universal language that enables communication between different
entities and layers of regulation’ [114].
For a long time, ROS and RNS were seen solely as damaging agents and drivers of diseases and aging. Nowadays
it is well known that they also play an important role as
regulatory mediators in signaling processes and as signaling
molecules for other physiological functions. It was realized
that redox regulation of cellular processes seems to be equally
important as the well-known cellular mechanism of phosphorylation and dephosphorylation of proteins, whereby both
processes are interconnected [115]. Generation of ROS and
RNS in cells is counterbalanced physiologically by antioxidative mechanisms resulting in a cellular ‘redox homeostasis’.
Simply spoken, at ‘physiological’ levels ROS and RNS activate signal pathways and initiate physiological processes. At
higher, ‘supraphysiological’ levels damaging processes are
caused. The latter situation was initially named ‘oxidative
stress’, which is ‘an imbalance between oxidants and antioxidants in favor of oxidants, leading to a disruption of redox
signaling and control and/or molecular damage’ [116]. It is
one hypothesis that the induction of oxidative stress resulting
in a controlled generation of ROS and RNS in the extracellular space was evolutionary and developed as part of the innate
immune system as a defense mechanism against bacteria
[117, 118]. Generally, oxidative stress can be generated
endogenously by cell metabolism but can also result from
exogenous influences. However, the stimulating or damaging
activity of ROS and RNS has no primarily quantitative aspects
but significantly depends on parameters like the specificity and
selectivity of ROS and RNS and the compartmentalization of
its production or occurrence inside the cell [119].
One of the central questions of redox biology—and so of
plasma medicine—is the question of the specific chemistry of
redox-based biological processes [113]. The specific analytics of ROS and RNS and its effects on biological molecules
and structures is an ongoing challenge both in redox biology
and plasma medicine. According to the actual state of knowledge, different ROS and RNS have different selectivity in their
reactivity with biological structures.
Among the ROS, the hydroxyl radical, OH, is the most reactive which reacts with most compounds. In living tissue, it
is typically generated from H2 O2 catalyzed by ferrous ions
(Fenton reaction). Because of the high reactivity, its lifetime
in a biological environment is short (∼10−9 s). Superoxide,
O2 − , is produced from molecular oxygen, O2 , as a byproduct of mitochondrial respiration (respiratory chain reactions).
It is much less reactive, more selective, and has, consequently,
a lifetime of few seconds. It reacts in a radical–radical reaction with NO, forming ONOO− , which is a highly potent
oxidant and RNS with a half-life of several seconds. Superoxide is rapidly transferred into H2 O2 by superoxide dismutases
(SODs) or in a self-dismutation reaction with another superoxide molecule. Hydrogen peroxide is relatively stable with a
half-life of months if it is stored in the absence of light and
trace metal contamination. It has a relatively high selectivity

4. Consequences of plasma treatment in cells
and tissues
4.1. Redox biology as scientific basis of plasma medicine

As was pointed out already in the previous chapters, ROS and
RNS are considered the most important components of CAP,
responsible for several biological effects. This fundamental
insight was summarized and continuously updated especially
by Graves [2, 109, 110]. It has opened up the door to the
well-established field of redox biology to explain and interpret
several biological effects caused by CAP, leading to the classification of plasma medicine as a field of applied redox biology
[111]. The role of redox-based effects in plasma medicine was
initially demonstrated indirectly when the presence of antioxidants or scavenger substances like N-acetylcysteine (NAC),
glutathione, or ascorbic acid (vitamin C) were able to reduce
or completely extinguish CAP-based biological effects in a
number of in vitro experiments using cultivated cells.
For ROS and RNS, the collective abbreviation RONS is
used, too. Moreover, because RNS usually contain oxygen, it
is also useful to take the abbreviation ROS for both ROS and
RNS. Finally, there are other reactive species in the physiological context like reactive chlorine species (e.g. hypochlorite,
ClO− ), or reactive sulfur species (RSS) that can also ROS
and RNS include free radicals, i.e. molecules with a single
unpaired electron, and nonradical molecules. Among the most
important ROS, hydroxyl radical, OH, or superoxide, O2 − , are
radicals, whereas hydrogen peroxide, H2 O2 , or singlet delta
oxygen, O2 (1 Δ), are nonradicals. The most important RNS,
nitric oxide, NO, is a radical. Chemically seen, reactions of
substances like ROS and RNS involve the transfer of an electron. In these so-called redox reactions, the loss of an electron
means that the substance is oxidized whereas the gain of an
electron means that the substance is reduced. The tendency of a
substance to be oxidized or reduced, respectively, is quantified
by its redox potential. According to this concept, it depends on
the respective reaction partners and their relative redox potentials whether a single substance will be oxidized or reduced.
Redox potentials of ROS and RNS important in redox biology
and plasma medicine are tabulated in [112].
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towards proteins containing thiol (-SH) groups. The enzyme
catalase transfers H2 O2 into oxygen and water. Singlet delta
oxygen, O2 (1 Δ), is a photo-excited ROS having a half-life of
around 10 μs. It reacts rapidly but selectively with histidine and
cystein groups in proteins, but also with unsaturated lipids and
partially with nucleic acids. The most important RNS, nitric
oxide, NO, is synthesized by nitric oxide synthases utilizing
L-arginin as the substrate. It regulates several biological processes including both intracellular and intercellular signaling
and is part of defense reactions of macrophages.
One way to classify the activity of ROS and RNS is its
differentiation into primary and secondary species. Primary
species are the superoxide radical, hydrogen peroxide, and
nitric oxide, whereas the hydroxyl radical and peroxynitrite
can be seen as secondary species resulting from reactions with
primary species or a transition metal. There are some hints
that primary species in most cases reversibly react with the
target molecules and are, therefore, more associated with signaling processes. Primary species are well controlled, e.g. by
enzymes like SOD, or catalase and have only a weak damaging
potential. Secondary species are worse controlled and mainly
cause irreversible reactions and are therefore, more associated
with damaging processes. It is hypothesized that—against the
background of evolution—primary species are mostly responsible for physiological signaling whereas secondary species
serve for extracellular actions, e.g. killing of bacteria, and are,
at the same time, also able to cause damage to the cell [118].
Generally, the primary species superoxide and hydrogen peroxide are seen to be the major signaling molecules in cell physiology. However, this seems to be a very superficial and only
orientating categorization.
A crucial mechanism of redox signaling is based on the oxidation of protein sites containing cysteine which has a thiol
(-SH) group, mainly by hydrogen peroxide or superoxide. Oxidation of the thiol group to the sulfenic form (-SOH) results in
allosteric changes of the respective protein and subsequently
in altering is function (e.g. activation vs inactivation). Enzymatic reduction of sulfenic groups back to the thiol group by
thioredoxins or glutaredoxins can make this protein modification reversible. Higher levels of ROS may further oxidize
thiol groups to sulfinic (-SO2 H) or sulfonic (-SO3 H) residues.
These reactions are irreversible and lead to permanent protein
modification or damage. This is a simple example to demonstrate the balance between redox signaling on the one hand and
damaging oxidative stress on the other, in living systems, by
regulation of both the intracellular ROS level and the locally
available enzyme activity. For more insight into the cysteinebased redox signaling, see [120, 121].
ROS and RNS can be produced by various endogeneous
and exogeneous sources. The intracellular steady state is controlled by enzymatic (e.g. SODs, catalases, peroxidases) and
nonenzymatic (e.g. small-molecular weight substances like
vitamin E, vitamin C, glutathione, ubiquinone, beta-carotene)
antioxidant mechanisms and adaptive responses leading to
antioxidant gene expression. Following the rapid increase
in knowledge of redox biology in recent years leading to
much more insight into the well-balanced cellular redox
system, the concept of ‘oxidative stress’ was reassessed

to meet the fact that oxidative impact (‘oxidative stress’)
includes both the redox-caused damage and redox signaling,
as well as its sophisticated regulation in living systems. Low,
‘physiological’ exposure of ROS and RNS facilitates addressing specific targets to induce redox signaling. This state is
named ‘redox eustress’. High, ‘supraphysiological’ exposure
results in disrupted redox signaling and/or damage of biological structures. This situation is named ‘oxidative distress’
[116]. It will become apparent that this concept can be well
adapted to the different activity of CAP in biological processes
(see section 4.2).
In general, redox biology, as well as the concept of
oxidative stress and redox homeostasis, is much more complex than can be explained in this paper. For more detailed
insight, several review papers and books are available, e.g.
[113–115, 117, 119, 122–128]. However, this short introduction to the basic concepts of redox biology should be helpful in understanding the basic principles and mechanisms
of biological CAP effects and the consequences for medical
applications.
4.2. Fate of plasma-generated ROS and RNS in biological
systems

A central question of basic research in plasma medicine was
how the biological CAP effects are transmitted into living systems, i.e. how plasma ‘components’ reach cellular targets and
induce biological effects.
Plasma contains highly motile electrons and is conductive.
Therefore, it can transfer electrical current to cells and tissue
with possible biological consequences [129]. Likewise, emitted electromagnetic radiation, above all, UV light, generally
may elicit biological effects [130, 131]. However, with the
intensity as these physical plasma components arise in CAP
application, their cellular impact should be more or less negligible. Nevertheless, their combined effect during direct plasma
treatment, as well as their supporting impact generating reactive species in plasma–liquid interaction, should be kept in
mind and needs more research.
An important step to gain deeper insights into biological
plasma effects was the discovery of ROS and RNS as the most
dominant plasma effectors and that these plasma-generated
ROS and RNS are more or less the same as that are acting in regular cell physiology. Consequently, plasma treatment may be understood as a kind of ‘local oxidative stress’
terming plasma medicine as ‘applied redox biology’ following
the concept of Sies (figure 21) [111, 116].
Another important step was the generalizing statement that
all living systems are surrounded by liquid phases, i.e. the primary contact of plasma with living systems might be in most
cases a plasma–liquid interaction. This led to intensive investigations into the mechanisms of plasma–liquid interactions
(see section 3).
Even if this research led to an important increase in knowledge about the fate of plasma components in biological applications, it has to be taken into account that this research was
primarily based on in vitro experiments with bulk liquids or
cell cultures in which the covering liquid phase is comparatively bulky. In real setups, this situation may be distinctly
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different, e.g. in wounds that may be covered by a very thin
liquid film, or in the case of dry skin where it is not a liquid
film that is the primary target of plasma impact but the Stratum corneum, a μm thick protective layer. Consequently, the
situation is much more complex and needs more differentiated
consideration.
Generally, reactive species generated in the plasma/gas
phase (referred to as ‘source’ in figure 21) have to be transported to the biological target and, subsequently, have to be
exposed to biological structures to react with. Initially, the
transport and effective range of reactive species from the
plasma/gas phase in the biological environment and their subsequent biological impact strongly depends on the extracellular matrix composition (referred to as ‘sink’ in figure 21). It
is necessary to take into account that the extracellular space
in living tissue contains proteins, carbohydrates and other
components that are potential reaction partners for plasmagenerated reactive species. The dimension of the liquid layer
around cells—if present—as well as its composition strongly
influences the free range of reactive species, which is otherwise
determined by their reactivity (see section 4.1 or the review
paper [132]).
Provided that there is an albeit thin liquid phase between
the plasma/gas phase and the biological target (cell), different processes have to be taken into account [112]: (i)
gas phase transport of reactive species as was mentioned in
section 2.2; (ii) processes at the plasma/gas–liquid interphase;
(iii) processes inside the liquid. At the interface, both dissolvation of plasma/gas phase species into the liquid (see
table 1 in section 1) and desolvation of species (above all water
molecules) from the liquid into the vapor phase may occur.
Generally, the liquid phase can serve as a transport medium
to bring ROS and RNS from the plasma/gas phase to the biological target, or as a reaction medium where ROS and RNS
from the plasma/gas phase may react with other molecules of
or within the liquid to generate secondary reactive species.
Affected both by the reactivity of different reactive species
and the presence of potential reaction partners in the liquid
phase (cellular environment), the free range of reactive species
may be different. It is a consensus that short-lived ROS and
RNS rapidly decay in aqueous liquid resulting in more stable
species like nitrite, NO2 − , nitrate, NO3 − , or hydrogen peroxide, H2 O2 . Therefore, the plasma/gas–liquid interphase has
a special role because there is an accumulation of higherreactive species possible allowing chemical reactions that are
not realizable in the bulk liquid. Additionally, photochemical
effects of UV may occur in this interphase dependent on the
type of plasma discharge and the contact of the plasma with
the liquid, which may support the generation and/or conversion of ROS and RNS [70]. Therefore, it can be stated generally that the dimension and the composition of the liquid
phase around a biological target may be decisive for the fate
of the reactive species from the plasma/gas phase as well as
for their biological impact. Hence, any conclusions by analogy from in vitro experiments with classical 2D cell culture
models to the real situation e.g. in a wound, have to be considered with caution due to the possibly different liquid phase

dimensions as well as the different-by-composition cell culture media involved. These effects also have to be taken into
account if the biological activity of plasma-treated liquids
is considered in comparison to direct plasma treatment (see
section 3).
Looking further at the cellular level, the most important
biological structures for an impact of ROS and RNS are (i)
the cell membrane comprising a phospholipid bilayer containing cholesterol, proteins, and glycolipids; (ii) intracellular proteins; and (iii) nucleic acids (DNA, RNA) inside
the cell (figure 22). Because of their different localization,
accessibility for plasma-generated reactive species should be
different, too.
The cell membrane can be seen as the key target for the
impact of plasma-generated ROS and RNS. Some reactive
species such as ozone, nitric oxide or atomic oxygen are
able to penetrate biological membranes; others cannot because
of their polarity, e.g. singlet delta oxygen, hydroxyl radical,
superoxide anion, nitrite, or peroxynitrite. Hydrogen peroxide
is known to be able to diffuse into the cell via protein channels
called aquaporins. Moreover, cell membrane permeability and
fluidity can be further increased or modulated by plasma treatment via a decrease of the mechanical strength and improvement of pore formation based e.g. on lipid peroxidation. This
can be supported by plasma-transmitted electrical fields [133].
Plasma-generated ROS and RNS may penetrate cell membranes or interfere with them, inducing the generation of
secondary effects inside the cell. Stimulation of the intracellular production of ROS and RNS can amplify reactive plasma
species-based biological effects. In all cases, intracellular
redox signal cascades and response mechanisms are activated.
There are several reaction chains and mechanisms involved
that are as yet only partially deciphered. Privat-Maldonado
et al [134] give more details on plasma effects on cellular
membranes and their consequences for cell physiology.
As was pointed out already, all these hypotheses are more
or less based on the model representation that there is a simple system containing a plasma/gas phase, a liquid phase (with
different roles of the plasma/gas–liquid interphase and the
bulk liquid), and the cell, with the cell membrane as the primary target of impact of plasma-generated compounds. Even
if this simple model was the basis of important progress in
understanding biological plasma effects, it cannot completely
explain some plasma effects in deeper layers of tissue where
a direct plasma impact must be considered as unlikely. Early
reported examples of biological depth effects after plasma
treatment of intact skin were an increased oxidation of betacarotenes (which are part of the antioxidant network of the
human skin) or an increased number of proliferating cells
in deeper skin layers [135, 136]. Moreover, increased tissue oxygenation and blood circulation were found after both
plasma treatment of intact skin [137–140] and skin wounds
[141–143]. Even if for the latter effects physical phenomena
like plasma-transmitted electrical fields may be at least partially responsible, in general, such effects in deeper skin and
tissue layers cannot be explained completely by direct plasma
action.
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Generally, there are three mechanisms under discussion
which may explain plasma effects in deeper skin and tissue
layers: (i) diffusion of plasma-originated or secondary generated long-lived ROS and RNS into deeper tissue layers; (ii)
action of proteins with plasma-caused posttranslational modifications or other oxidized biomolecules; and (iii) stimulation of cell–cell communication after direct exposure of surface cells to plasma or plasma-generated species, respectively
(figure 23).
More so than in plasma–liquid interaction, it is challenging
to follow and detect trajectories of ROS and RNS inside tissues. Therefore, several more or less complex in vitro models
for tissue penetration of plasma-generated species were used
and complemented by computational methods. For details on
these approaches, see the review papers [134, 144–146]. In
these models, penetration depths of plasma-derived ROS and
RNS from 5 μm up to several mm were proposed, dependent on the models used, experimental conditions, as well as
evaluation methods.
Furthermore, oxidative modifications of organic molecules
were identified to play an important role in the transmission
of biological plasma effects. Here, cysteine thiol groups are
important target structures [147, 148], not only for redoxbased signalling as mentioned in section 4.1. It was also found
by in vitro experiments that plasma-treated cysteine might
exert distinct biological effects in cells [149]. Such modifications of cysteine groups as well as other plasma-induced
posttranslational peptide or protein modifications [150, 151]
may be responsible for prolonged secondary effects of plasma
treatment also in deeper tissue layers.
Finally, because a diffusion of plasma-generated ROS and
RNS, as well as secondary species generated inside the tissue into deeper skin and tissue layers might also be limited
because of their limited range in a biological (reactive) environment, so-called ‘bystander’ or paracrine effects should give
another satisfactory explanation for depth effects [2, 109, 134].
A very early idea of possible cell–cell communication based
on molecules secreted by plasma-treated cells was given by
Kalghatgi et al, who demonstrated in vitro that endothelial
cells treated with plasma release the fibroblast growth factor-2
(FGF2). The FGF2 stimulates proliferation of other cells that
are not plasma treated. These experimental results suggested
that plasma treatment might enhance endothelial cell proliferation due to reactive species-mediated FGF2 release [152].
Meanwhile, there is incidence from several in vitro and in vivo
experiments that such cellular secretion of growth factors and
cytokines is an obvious cellular response to plasma treatment
(see section 4.3).

(see section 4.1), mammalian cells have a well-balanced system to control the intracellular redox state based on sophisticated redox-controlled reaction chains. The phenomenon of
low concentrations of agents having different effects compared to higher concentrations is known as hormesis. It can
also be adapted to the ROS/RNS-based biological plasma
activity [109, 134].
One of the key translators of redox signalling in cellular response against imbalances in redox homeostasis is
the nuclear factor erythroid 2-related factor (Nrf2) pathway
[124, 153–155]. Under physiological conditions, Nrf2 is associated with the action-binding Kelch-like ECH-associated protein 1 (Keap1). This binding sequesters Nrf2 in the cytoplasm
and leads to its rapid proteasomal degradation to maintain
baseline Nrf2 levels with a half-life of 20 min. By redox modification of thiol (-SH) groups of cysteine-residues of Keap1,
Nrf2 is released from its complex and translocates from the
cytoplasm to the nucleus where it dimerizes with small musculoaponeurotic fibrosarcoma proteins and binds to antioxidant responsive elements (ARE) on DNA. This promotes the
upregulation of antioxidant genes, which encode detoxifying enzymes and proteins like glutathione (GSH), glutathione
reductase (GSR), glutathione S-transferase (GST), superoxide dismutase (SOD), heme oxygenase 1 (HMOX-1), thioredoxin (TXN), and NADPH quinine oxidoreductase 1 (NQO1)
(figure 24).
According to the actual state of knowledge, this pathway
is one of the most active regulatory networks also in response
to plasma treatment [134]. It was repeatedly demonstrated in
vitro but also in animal studies in vivo, that CAP treatment
is able to stimulate this Nrf2 pathway resulting in subsequent
activation of Nrf2-ARE targets [157–159]. The fact that the
Nrf2 pathway is induced by CAP treatment is a strong support
of the concept of CAP-induced oxidative stress response of
cells as it is shown in figure 21.
Stimulation of the Nrf2 pathway by CAP treatment can be
taken as one of the mechanisms to protect mammalian cells
from genotoxic plasma effects. A huge number of in vitro
studies report on potential genotoxic CAP effects on isolated,
naked, or cellular DNA [160]. However, estimation of genotoxic effects of CAP by in vitro standard procedures for mutagenicity testing did not result in an extended mutation rate of
plasma-treated cells [161–165]. This was confirmed by an animal study using hairless immunocompetent mice [166], and
in clinical follow-up investigations of plasma-treated wounds
[167, 168], where consistently no precancerous lesions or
other signs of skin or tissue alteration where found that could
give evidence of cancer formation. For a review on safety
aspects of CAP application, see also [169].
Besides its central role in cytoprotection, there is some evidence that activation of the Nrf2 pathway also has a major
impact on wound healing. It was reported that Nrf2 activation
can stimulate the proliferation and migration of epithelial cells
during wound repair. Nrf2-activating compounds are estimated
to be a promising therapeutic approach in wound healing
[154, 155, 170].
Above all, in an acute wound healing study on mice, an
early activation of the Nrf2 pathway was demonstrated in vivo

4.3. CAP-triggered biological signaling in oxidative stress
response, wound healing and cancer treatment

As was explained before, the decision regarding whether
a plasma treatment induces oxidative eustress or distress
depends on (i) the amount of ROS and RNS reaching the biological target (determined by their production by the plasma
device—‘source’, and their modulation by the liquid environment—‘sink’); and (ii) on the adaptive response of the biological system itself (see figure 20). As was pointed out already
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and ex vivo in skin tissue, dermal fibroblasts and epidermal keratinocytes [159]. Besides the key role of the Nrf2 system in the
upregulation of detoxifying and antioxidant genes, activation
of Keap1 stabilizes the architecture of F-actin cytoskeleton and
focal adhesion, and increases granulation tissue formation and
matrix deposition. As a key regulator in macrophages, Nrf2
mediates the infiltration of macrophages and neutrophils and
the upregulation and secretion of pro- and anti-inflammatory
ligands, which activate signalling and intracellular generation
of ROS and RNS. CAP supports angiogenesis by the recruitment of endothelial cells, growth factor expression like keratinocyte growth factor, epidermal growth factor, or vascular
epidermal growth factor, and activates protein kinase B (Akt),
which are inducers of Nrf2 expression [111, 143, 156, 159].
Besides the Nrf2 pathway, other proliferative-acting pathways like the MAPK/ERK pathway (mitogen-activated protein
kinases/extracellular signal-regulated kinases) or the Hippo
signalling pathway are identified in plasma-treated skin cells
in vitro [134, 171–174].
Because wound healing is a complex and multi-stage process [175, 176], not only proliferative, but also apoptotic
effects are necessary to manage the removal of inflammatory
cells and to inhibit scar formation of granulation tissue in the
later parts of wound healing. Here, as another redox-sensitive
transcription factor, the tumour suppressor protein p53 plays a
role in the regulation of cell proliferation and apoptosis, but
also in angiogenesis, cell cycle regulation and DNA repair
[177, 178]. Its activity depends on the state of wound healing and the concentration of reactive species and is linked to
the Nrf2 system. At low p53 expression levels, it enhances
the Nrf2 protein level, whereas at high p53 expression the
Nrf2 mediated cell response is inhibited and cell senescence
or apoptosis is supported. It was demonstrated repeatedly that
this p53 signalling pathway is also triggered by CAP treatment
[111, 134, 179].
Taken together, based on a huge number of in vitro
results, that are verified in vivo in some animal trials, important details of CAP-supported stimulation of tissue regeneration and wound healing were uncovered, mainly leading to
[156, 158]:

According to the concept of oxidative eustress and distress
that was adapted to plasma medicine (see figure 21), support
of tissue regeneration by CAP treatment can be assigned to
redox-regulated ‘oxidative eustress’. Following this concept, a
more intensive (longer) plasma treatment resulting in a higher
impact of ROS/RNS must lead to an overburdening of adaptive
responses of the cell and, consequently, to dysregulation and
cell death [183, 184]. Indeed, this phenomenon of the stimulation of cells with shorter plasma treatment time and the
inhibition of cellular function up to cell death after longer treatment times was described in vitro repeatedly; see for example
[136, 185]. That means, on the one hand, that a careful application of plasma is necessary with parameters that are strongly
dependent on the specific characteristics of the plasma source
used if stimulation effects, e.g. in wound healing, are intended
in an optimized manner. On the other hand, CAP can also be
used to inactivate cells in a controlled manner.
It is one of the early findings of fundamental research in
plasma–cell interactions that CAP is able to inactivate cancer
cells. A huge number of in vitro experiments, but also first animal experiments, could demonstrate the anticancer effects of
CAP; see [12, 186, 187]. This is important as well as relevant
for potential medical applications of CAP in the field of cancer
therapies because the evasion of apoptosis is one of the hallmarks of cancer [188, 189]. It was proven that different cancer
cell lines are very different in their sensitivity to plasma impact
[190–192], and that cell type, cancer type and cell culture conditions strongly influence CAP effects, on the one hand [193],
but also the tumor microenvironment containing malignant
cells, endothelial cells, fibroblasts, tumor vasculature and the
extracellular matrix on the other [194]. Nevertheless, it is a current hypothesis that cancer cells are generally more sensitive
to CAP treatment compared to nonmalignant counterparts.
ROS/RNS are main contributors for the efficacy of CAP
in killing cancer cells [183] because they are able to trigger different specific intracellular mechanisms leading to cell
cycle arrest or cell death via necrosis or apoptosis, a form of
regulated cell death [195]. Other processes like senescence,
an irreversible cell growth arrest in response to stress like
oxidative stress and DNA damage, or autophagy, a lysosome
dependent cellular mechanism to remove needles or impaired
components, were also described.
CAP-induced cell death via ROS/RNS impact is a complex
process about which the details are still only partly understood. If increased levels of plasma-generated ROS/RNS occur
inside the cell, direct oxidative change of cellular lipids, proteins, or nucleic acids may lead to its general damage or dysfunction. Moreover, a variety of intracellular processes may
be influenced, including caspase activation, cell-cycle disruption and disruption of other multiple pathways. For example,
apoptosis can be induced by triggering specific pathways like
the MAPK/ERK pathway, which is not only a regulator of
cell proliferation, but also related to apoptosis. ROS/RNS signalling is also coupled to calcium signalling. Calcium is an
important second messenger that is involved in cell life and
death decisions. The main intracellular storage of calcium is
the endoplasmatic reticulum (ER), where calcium is released

• Promotion of re-epithelialization and the acceleration of
wound closure,
• Reduction of inflammation by activation of cytoprotective
mechanisms and by recruiting of immune cells into the
wound area,
• Fibroblast activation inducing rearrangement of the actin
cytoskeleton and promoting matrix synthesis,
• Activation of wound healing-relevant cytokines and
growth factors in fibroblasts and keratinocytes, and
• Induction of neovascularization.
Finally, increased tissue oxygenation and blood circulation caused by plasma treatment, as mentioned above (see
section 4.2), are additional factors of wound healing support. Moreover, it was demonstrated repeatedly in vitro and
in vivo, that CAP also promotes blood coagulation; see for
example [180–182].
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by specific receptors that are sensitive both to ROS and to calcium. Increased ROS/RNS, as well as calcium concentration
in cells after CAP treatment, are features of ER stress. A specific connection of ER with mitochondria allows the exchange
of calcium, lipids and metabolites. ER stress, e.g. caused
by enhanced ROS impact, leads to increased calcium content in mitochondria and subsequent depolarization of mitochondria membrane potential. This in turn causes a release
of cytochrome c activating mitochondria-dependent apoptosis. Another pathway resulting in mitochondrial apoptosis is
triggered by NO, via blocking cytochrome oxidase, the terminal enzyme of the electron transport chain in mitochondria.
These are only some examples of molecular mechanisms of
CAP-induced cell death. More details are explained in several
review papers, e.g. [134, 186, 191, 194, 196].
As was pointed out already, the balance between oxidative eustress and distress is finally defined by the amount of
ROS/RNS inside the cell and its impact on intracellular regulatory mechanisms. Consequently, both stimulation and induction of cell death are possible in principle in any type of mammalian cells. However, the most interesting question is how
to explain the predicated higher sensitivity of cancer cells to
oxidative distress.
On the one hand, there are generally increased steady-state
ROS levels in cancer cells resulting from unique metabolic
activities [124, 197]. Therefore, cancer cells might be more
vulnerable to further oxidative stress caused by CAP application because the toxic threshold might be reached earlier compared to nonmalignant cells. Additionally, the anti-oxidative
defence system based on enzymatic and nonenzymatic mechanisms (see section 4.1) may be different in cancer cells
compared to their nonmalignant counterparts.
On the other hand, the enhanced plasma sensitivity of cancer cells is explained by a selective stronger rise of intracellular ROS/RNS caused by specific characteristics of cancer
cells. The first barrier that is tackled and has to be overcome
by plasma-caused ROS/RNS is the cell membrane. Because
of its hydrophilicity, the direct transmembrane diffusion of
ROS/RNS is limited. Transmembrane channel proteins called
aquaporins serve as water channels facilitating the transport
of water between cells but also enabling diffusion of small
hydrophilic molecules. An increased expression of aquaporins in cancer cells may be one cause for increased impact
of ROS/RNS and resulting in the higher sensitivity of cancer cells to plasma treatment. On the other hand, the diffusion of ROS/RNS through phospholipid membranes depends
on the cholesterol content providing membrane stability and
fluidity. The amount of cholesterol is often reduced in cancer
cells. Lipid peroxidation caused by ROS/RNS may contribute
to additional pore generation in such cholesterol-depleted cell
membranes. Selected aspects of plasma selectivity to cancer
cells in comparison to normal cells are presented schematically
in figure 25; see also [2, 190, 198, 199].
A further hypothesis under discussion is based on an
enhanced cell-based generation of H2 O2 via plasma-generated
superoxides by extracellular superoxide-dismutase on the cell
membrane and a subsequent triggering of immune attack
on cancer tissue by H2 O2 -mediated lymphocyte activation

[200]. Another redox-regulating enzyme is catalase, which is
expressed to a higher extent on cancer cell surfaces to protect them from intercellular ROS/RNS-dependent apoptosisinducing signaling. Plasma-generated singlet delta oxygen,
O2 1 Δ, is supposed to inactivate membrane-bound catalase
which leads to the generation of tumor cell-derived secondary
singlet delta oxygen in a self-perpetuating manner catalyzed
by transmembrane NADPH oxidase (NOX) resulting in selective ROS/RNS-dependent apoptosis in tumor cells [201]. All
these hypotheses are more or less feasible but currently still
under discussion [192].
Finally, it has to be mentioned that substantial in vitro and
in vivo evidence provided that redox-based effects of CAP
causing cell death may also have immunomodulation aspects.
CAP is able to affect immune cells, which is mainly investigated in conjunction with cancer treatment. There are hints that
CAP treatment may lead to systemic tumor-specific immunity
[202]. Current results in this field are summarized in [203].
Several studies reported that plasma-treated cancer cells succumb to the so-called immunogenic cell death (ICD) promoting anticancer immune responses, which was observed before
e.g. in radiotherapy [204, 205]. ICD is a regulated cell death
mechanism aligned with the adaptive immune system. Cells
undergoing ICD release so-called danger-associated molecular patterns to communicate with immune cells. This includes
active secretion of adenosine triphosphate (ATP) or mobilization of calreticulin (CRT) to the outer cell surface. As a result,
so-called antigen-presenting cells (APC), i.e. macrophages
and dendritic cells are alerted. Attracted by ATP and finding
surface CRT, the cancer cells are phagocytised with the cell
fragments serving as antigens. Antigen-loaded APCs stimulate
the generation of antigen-specific T-cells and memory cells. As
a consequence, these circulating cells can then target other cancer cells of the same origin, e.g. metastatic cells, that are not
CAP treated [206–209]. Such ICD processes are one explanation for abscopal plasma effects, i.e. reduction of growth of
tumors in animal experiments that were not exposed to plasma
treatment but are localized elsewhere in the same animal
[210, 211]. This may open a highly promising therapeutic
approach for cancer treatment in cases where direct plasma
control of a metastatic lesion cannot be realised. Moreover,
these immune-modulating effects of plasma may open up
novel strategies of vaccination [212], but may also have potential consequences with regard to systemic effects of a local
therapy by CAP.
To close this chapter on CAP-triggered biological signalling, it has to be mentioned explicitly that most of the biological effects of CAP are not only caused by direct CAP
application but also by application of plasma-treated liquids, sometimes called ‘indirect’ plasma application [213].
This underlines the crucial role of plasma-caused ROS/RNS
that generated in or transferred into liquids (see section 3).
On the other hand, such plasma-treated liquids, which are
often called plasma-‘activated’ liquids (e.g. plasma activated
medium, PAM, or plasma activated water, PAW), seem to open
up very promising therapeutic approaches above all in cancer therapy [93–95, 214]. However, despite a general equivalence of basic anti-cancer effects, there seem to be some
25
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Figure 25. Schematic representation of selected aspect of plasma selectivity to cancer cells. Reprinted from [199],with the permission of
AIP Publishing.

differences between direct plasma treatment and the application of plasma-treated liquid. In direct plasma treatment,
three plasma related factors may become active: (i) physical
plasma components; (ii) short-lived reactive species occurring
directly from the plasma impact; and (iii) long-lived reactive
species generated in liquid phases. In plasma-activated liquids (PAL), only long-lived reactive species should be active.
There are some hints in the literature that both short-lived
reactive species and physical factors may be active in some
sensitization of cancer cells, finally causing additive or synergistic effects together with any ‘basic’ activity of long-lived
reactive species [215]. Recent reports on anti-cancer effects
of CAP only based on physical impact may lead to new
insights into the unique characteristics of CAP in biomedical
applications [216, 217].

vation of microorganisms by CAP is still limited. There are
some reports on mechanisms of low-pressure cold plasma
interaction with microorganisms which is mainly attributed to
UV-based DNA damage in combination with erosion of
microorganism structures by UV-based photodesorption and
etching processes by reactive plasma species [227–229]. However, these mechanisms are not fully transferable to atmospheric pressure plasmas.
Supposed mechanisms of CAP effects on microorganisms are reported in some review papers, e.g.
[14, 219, 221, 223, 230–232]. Here, only a brief summary of
the current knowledge in this field will be given.
In general, the antimicrobial effectivity of CAP depends
on plasma processing parameters, environmental factors, and
properties of the respective microorganisms [219, 223]. Processing parameters include input power, treatment time, working gas type and flow rate, and exposure mode determined
by device characteristics. In the end, all these parameters
determine the composition and quantity of biologically active
plasma components.
Antimicrobial plasma effects are not only promising for
therapeutic applications like wound healing or pathogenassociated skin diseases, but also in hygiene and food
processing. Therefore, the surface or matrix where the
microorganisms are treated may be variable. Above all, humidity is a determining factor, i.e. if the microorganisms are treated
in a dry state or in a wet or liquid environment.

4.4. Cold atmospheric plasma effects on microorganisms

With the improved availability of CAP technology in the 1990s
[218], the first ideas to use it for biomedical applications
resulted from its strong antimicrobial activity [13, 219]. Meanwhile, there are plenty of reports on CAP inactivation of bacteria including bacterial biofilms, fungi, bacterial spores, and
viruses, summarized in review papers such as [220–226].
In contrast to the huge research effort in recent years to
elucidate mechanisms of plasma effects on mammalian cells
including cancer cells, knowledge of mechanisms of inacti26
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Microorganisms’ sensitivity to CAP is different and
depends not only on microorganism species but also on growth
phase and mode of growth. Even if there is no general
consensus, gram-negative bacteria with outer membranes of
lipopolysaccharides and a thin (∼2 nm) cell wall consisting of
peptidoglycan are reported to be more susceptible to CAP than
gram-positive bacteria with a thicker peptidoglycan cell wall
(∼40 nm) and no outer membrane. Some bacteria like Bacillus
subtilis are able to pass over from a vegetative to a sporulated
state with hard and multi-layered coats; these bacteria spores
are hard to inactivate by CAP. Finally, the resistance of fungi
to CAP is usually higher, compared to bacteria. Here, the fungal cell wall consisting of chitin, which is more rigid than the
peptidoglycan bacterial cell wall, may be critical. Many bacteria and, above all, human pathogens are able to form biofilms,
i.e. sessile bacterial communities attached to a substratum or
to each other that are embedded in a matrix of extracellular
polymeric substances (EPS). These biofilms are highly coordinated communities with a—compared to planktonic bacteria—higher resistance against environmental stress including antimicrobial measures, and are difficult to inactivate or
remove using CAP [225].
Similarly to mammalian cells including cancer cells, microbicidal CAP effects are mainly attributed to the activity of ROS
and RNS. UV effects as in low-pressure plasma do not seem
to be the major inactivating factor because of low UV doses
and UV absorption by ambient atmospheric air. Some proposed and mainly ROS/RNS-based inactivation mechanisms
of microorganisms are depicted schematically in figure 26.
Antimicrobial CAP effects are mainly attributed to three
general actions: (i) permeabilization or damage of cell membrane or wall, (ii) modification or damage of intracellular
proteins, and (iii) DNA damage.
There are some hints that there is some balance between
biological impact on cellular processes and physical destruction of bacteria dependent on the intensity of plasma application [233, 234].
Damage to the cell membrane or cell wall can be caused
by oxidative impact of plasma-generated reactive species on
the one hand and, under specific conditions, by electrostatic
disruption resulting from accumulation of charged particles
generated from plasma on the other. Because of the strong
dependence of the effect of the electrostatic forces on the
cell radius, microorganism cells may be more susceptible to
this physical impact than mammalian cells because the latter are usually one order of magnitude larger. In both cases, a
leakage of intracellular components like nucleic acid and protein, but also an increased influx of ROS/RNS into the cell,
can be the result. Another possible mechanism to enhance
ROS/RNS influx is an electroporation-like effect of high electrical field originated from plasma. This effect, sometimes
called ‘plasmaporation’, is reported for mammalian cells (see
e.g. [235–237]), but is also discussed for microorganism cells
[238]. Indeed, a synergistic antibacterial effect of combined
treatments of CAP and pulsed electric fields (PEF) was demonstrated [239].

Moreover, products of lipid peroxidation of the membrane
of Gram-negative bacteria (Escherichia coli) like malondialdehyde are reactive enough to damage DNA and proteins inside
the cell.
Inside the cell, several proteins but also DNA are the target of ROS/RNS. In procaryotic cells like bacteria (but not
in fungi), DNA is localized in the nucleoid region, but it is
not separated by a membrane-bound nucleus from the other
cell content. Therefore, DNA might be more susceptible to
intracellular ROS/RNS than eukaryotic mammalian cells. The
occurrence of ROS/RNS in microorganism cells after plasma
treatment is indicated by the upregulation of antioxidative regulatory proteins like OxyR and SoxS in E. coli, but also catalases, peroxidases, and SODs. It was also reported that several
genes of the SOS response are upregulated, which is a broad
regulatory network in most bacteria to counteract DNA damage [160, 240]. Dependent on the intensity (time) of CAP treatment, both DNA damage and the damage to several proteins
including enzymes was reported.
Consequently, cell lysis is not the only mechanism of
plasma-caused inactivation of microorganisms. There are several physiological and morphological changes of microorganism cells before they are inactivated. More and more
studies indicate that also in bacterial cells an apoptosis-like
programmed cell death occurs. It can be triggered by the accumulation of intracellular ROS/RNS [241]. This might be one
of the potential mechanisms of CAP-induced inactivation of
microorganisms.
However, the impact of CAP on bacteria cells may not necessarily result in terminal cell death. External cell stress is
able to cause a viable but nonculturable (VBNC) state that
is characterized by intact cell membrane, respiratory activity,
gene transcription and protein synthesis, but no cell division
and, consequently, no colony forming under laboratory conditions [242, 243]. This VBNC state was also reported for CAPtreated bacteria; see e.g. [244, 245]. Because bacteria in this
state are not detectable by conventional cultivation methods,
this has to be taken into consideration because it could lead
to maintenance of contamination or recurrence of infection,
respectively.
Particularly important for biomedical applications is the
fact that it was proven that a huge number of clinical isolates of
wound bacteria, including drug-resistant strains, can be eradicated by CAP. With regard to bacterial resistance to plasma,
there are few investigations, only, with divergent results. Here,
much more research is needed to clarify if this is a potential
point for attention in plasma medicine [246–249].
Summarizing this chapter on CAP effects on microorganisms, it can be stated that CAP has a promising potential to
be applied in several fields including plasma medicine. Nevertheless, more intensive and systematic research is needed to
explain the detailed mechanisms of inactivation of microorganisms by CAP. One of the central issues is if there is a
selectivity of biologically active plasma components between
microorganisms and human tissue and what are the reasons
or mechanisms of such a selectivity. Approaches to answer
27
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Figure 26. Proposed inactivation mechanisms of microorganisms by CAP; Reprinted from[223], Copyright (2017), with permission from

Elsevier.

these questions are required for different cell sizes and structures and different response mechanisms i.e. against oxidative
stress. Here, an interesting field of research is still open.

of well-proven local antiseptics or systemic antibiotic therapy
to reduce the microbial load of chronic wounds is undisputed.
Consequently, it was crucial to demonstrate that CAP is more
than a ‘local physical antiseptic’. Several clinical studies and
case reports in human volunteers or patients with well-defined
artificial acute wounds without microbial contamination or
infection, respectively, could reproduce the results from animal trials, that CAP application is also effective in stimulating
tissue regeneration directly, see e.g. [259–261].
Meanwhile, there are meaningful randomized controlled
clinical trials available where stimulation of chronic wound
healing by CAP was the first objective. In a clinical trial published by Stratmann et al 2020 [262], 62 diabetic foot ulcers
were CAP-treated over 14 days using the argon-driven plasma
jet kINPen MED. A significant reduction of the wound area
in the plasma group compared to a placebo group was found
(figure 27), whereas both CAP and placebo treatment reduced
the bacterial load of the wounds. It has to be noted that all
wounds received standard wound care including local disinfection and systemic antibiotic treatment if indicated. Therefore, this study demonstrated beneficial CAP effects on wound
healing based on direct stimulation of tissue regeneration
independent from antiseptic plasma effects in a randomized,
placebo-controlled clinical trial in a population-based, representative cohort of patients.
These results were confirmed in another clinical study
including 44 diabetic foot ulcer patients. In this study, a
helium-driven high-frequency (HF) plasma jet was used [263].
In a further clinical trial, 37 patients suffering from chronic
ulcers of different aetiology were CAP treated one time or
three times per week over twelve weeks maximum with the
argon-driven plasma torch SteriPlas. Here again, a significant
reduction of wound area was found in the CAP-treated groups.
Moreover, the CAP treatment three times a week was not

5. Therapeutic applications of cold atmospheric
plasma (CAP)
5.1. Wound healing

From the beginning, a central aim of application-oriented
research in plasma medicine was CAP application in wound
healing [3, 4, 250]. Above all, chronic wounds are an important
challenge for patients, health care professionals and health care
systems worldwide [251]. Plasma was estimated to have great
potential in this field because of its early-predicted effectivity, in two ways: to inactivate wound-contaminating microorganisms and to directly stimulate tissue regeneration [252].
In particular, the latter aspect was extensively researched in
vitro but also in animal experiments in vivo (see section 4).
Meanwhile, there are several clinical trials proving the woundhealing effectivity of CAP, summarized in review papers
[184, 253, 254].
The first clinical trials were mainly focused on the safe
application of CAP devices and the reduction of the microbial
load of chronic wounds, see e.g. [7, 255–257]. In these studies,
CAP application was used in addition to regular wound care
where antibiotic and/or antiseptic therapy was not excluded
generally. Moreover, in some studies CAP was tested against
local antiseptics. Any statements apllying to wound closure or
other indications of healing processes were avoided or mentioned marginally. Consequently, a first meta-analysis considering these studies concluded that the use of CAP ‘in wound
care is safe, but the retrieved evidence and meta-analysis
show that there is no clinical benefit . . . in chronic open
wounds’ [258]. This was not surprising because the effectivity
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Reported experimental and clinical results on direct stimulation of tissue regeneration by CAP make it also applicable in
the field of acute wound healing, even if acute surgical but also
traumatic wounds typically do not need additional stimulation
because they are healing regularly under physiological conditions. However, in cases where the risk of retarded healing is
enhanced because of the patient’s health status, CAP application may be promising, which has been proven in the first case
reports [268, 269]. Moreover, the use of CAP for the disinfection of primary and secondary wounds to avoid postoperative
wound infection is repeatedly discussed [270]. However, it will
be difficult to prove the clinical benefit of such preventive CAP
application directly. The same is with the question if any initial
acceleration of wound closure by CAP treatment as demonstrated experimentally in vivo [263, 271], has any positive
impact on scar formation [167]. Nevertheless, together with
possible preventive effects on wound infection, CAP treatment is mentioned as a promising option to support several
interventions also in the field of plastic surgery and aesthetic
medicine [272].
A specific CAP application close to wound healing, which
is extremely helpful for the patients concerned, is the treatment
of left ventricular assist devices (LVAD) driveline infections.
LVAD are mechanical support devices for patients with severe
acute and chronic heart failure [273, 274]. These implanted
devices are connected to an external power supply by a socalled driveline. The transcutaneous driveline exit site is a conduit for bacterial entrance with the risk of creating a bacterial
biofilm growing along the driveline into the body [275]. This
can become very dangerous for the patient because the removal
and replacement at another site of these driveline catheters is
impossible or intricate, respectively. Here, CAP and, above
all, the argon-driven jet devices kINPen and SteriPlas demonstrated repeatedly to be very effective tools to fight successfully such driveline infections [276–280].

Figure 27. Wound size reduction in 62 diabetic foot ulcers (placebo:
31, plasma: 31) after eight CAP treatments within 14 days (daily
treatment for five consecutive days followed by three treatments
every second day) in relation to start of therapy; visit nine: two to
three days after the last treatment. Reproduced from [262] © 2020
Stratmann B et al. JAMA Network Open. http://creativecommons.
org/licenses/by/4.0/

superior to the once-a-week treatment [264]. In a similar study,
another argon-driven HF plasma jet treated 50 patients with
pressure ulcers once a week over eight consecutive weeks additionally to standard wound care. Both a significantly improved
wound healing and a reduction in bacterial load was found
[265]. In a case series with 32 patients suffering from venous
and mixed leg ulcers, a daily treatment with a needle-type
helium-driven plasma device improved wound healing and
reduced pain [266].
Consequently, the support of chronic wound healing by
CAP is proven according to the current state of clinical
research. This is particularly remarkable against the background that generally in the field of wound healing few randomised, controlled trials of wound dressings, bandages etc,
which are classified as medical devices, are available because
wounds present as part of such a complex presentation that any
generalisation within the scope of a clinical trial is estimated
to be very difficult [267].
Based on long-term experimental and clinical research, first
CAP devices are on the market that are CE-certified as medical devices class IIa. Worth mentioning here are the argondriven HF plasma jet kINPen MED (neoplas med, Greifswald,
Germany), the argon-driven microwave plasma torch SteriPlas
(ADTEC, Hunslow, UK), and the DBD-based devices PlasmaDerm (CINOGY, Duderstadt, Germany) and plasma care
(terraplasma medical, Garching, Germany). The latter two
use atmospheric air as working gas. Currently, these devices
are mainly used in reconstitution or re-stimulation of healing
processes that are defective caused by other primary reasons
resulting in chronic wounds. The direct (initial) stimulation of
tissue regeneration is a unique characteristic of CAP with a
supportive role of antimicrobial/antiseptic plasma effect. First
devices are on the marked since 2013 with increasing successful application in clinical practice. Unfortunately, comprehensible and systematic documentation of this practical
experience beyond clinical studies is currently rare.

5.2. Dermatology

Beyond wound healing as the most investigated CAP application, there is some more potential to use plasma devices in a
wider context of dermatology [253, 281]. Single case reports,
clinical case series and clinical trials are available on CAP
treatment of several infective and inflammatory skin diseases
with different results.
A randomized placebo-controlled clinical trial is reported
including 37 patients suffering from herpes zoster, a viral skin
disease characterized by blister formation and painful skin rash
in a localized area. Weekday five-minute treatments with the
argon-driven microwave plasma torch MicroPlaSter (a predecessor device of SteriPlas) resulted in a more rapid clinical
improvement in the first one to two days in the plasma-treated
group, including acute pain reduction and initial healing of the
herpes zoster lesions [282].
In a randomized two-sided placebo-controlled study with
46 patients with different pruritic (itchy) skin diseases, a
2 min daily treatment with the MicroPlaSter argon plasma
torch additional to standard treatment did not result in higher
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pruritus reduction compared to placebo treatment with argon
gas only [283].
Another relatively widespread skin disease is psoriasis, an
autoimmune disease that is noncontagious and characterised
by sometimes-large areas of angry, dry, itchy, and scaly skin.
In a case series with six patients, a three-times-a-week treatment of psoriatic plaques with the argon-driven atmosphericpressure plasma jet kINPen showed no significant advantage
over conventional therapies. However, because minor positive effects were obtained, it was suggested that it might be
worth testing combinations of CAP with conventional topical
or systemic therapeutic procedures [284].
Mainly based on the antimicrobial and antiviral effectivity
of CAP, single clinical investigations have demonstrated the
successful CAP effect on onychomycosis (fungal infection of
the nail) and warts [285–287].
Generally, experience of different and more or less successful dermatological applications are mainly anecdotic so
far, and are rarely documented or reported in larger case
series. However, it is known that medical doctors that are
engaged in plasma medicine also try to use CAP in different
dermatological indications beyond wound healing.
Very close to therapeutic dermatological applications is the
field of plasma applications in cosmetics. It has to be stated that
there is not always a clear distinction possible between therapeutic use as it is intended with plasma medicine devices and
improvement of appearance, as it has to be intended with cosmetics as well as aesthetic medicine. For instance, CAP application in acne treatment might be focused on both the healing
of a skin disease and aesthetic skin improvement [288]. Particularly on the World Wide Web, there are several proposals
that offer promising effects of plasma application for corrective treatments and skin improvement, some of them explicitly referring to plasma medicine. Most cosmetic indications
of plasma treatment are focused on skin tightening, wrinkle
removal, face and body lifting, skin rejuvenation, or blepharoplasty (tightening of eyelids). The techniques are often based
on needle-like devices where an electrical spark is generated
between the needle-tip and the skin, resulting in dark spots on
the skin because of tissue carbonization that resolves during
the following days; see e.g. [289, 290], or search the World
Wide Web using a keyword like ‘plasma cosmetics’. Nevertheless, these applications are often described as ‘noninvasive’
and ‘nonthermal’. The best described and investigated plasma
device for cosmetic and aesthetic applications is the nitrogen
plasma-based jet-like Portrait PSR3 system, which is mainly
used for skin regeneration. However, its effectivity in acne
treatment is also reported. Its activity is based on instantaneous
skin heating in a controlled, uniform manner without an explosive effect on tissue or epidermal removal; see e.g. [291–294].
Because most of the known applications of plasma for cosmetic purposes are based on more or less intensive thermal
effects, any reference to plasma medicine in terms of this foundation paper, above all, with respect to safety, is illegitimate
because nearly all recent investigations into plasma medicine
are based on NTP–cell and plasma–tissue interactions. On
the other hand, there are several approaches indicating that
CAP might also be a promising tool for the stimulation and/or

regeneration of skin and, therefore, useful for cosmetic applications. A forward-looking review on the potential of CAP
for skin treatments is given in [295]. In particular, the repeatedly reported CAP effect to enhance skin permeability and to
enhance the transcutaneous penetration of substances may be
promising both for cosmetic purposes and for transcutaneous
drug release, but needs much more research, above all, in vivo;
for more details see e.g. [281, 296–300].
5.3. Cancer treatment

Because of the very promising results in experimental in vitro
research as well as in animal experiments [9, 12, 22], CAP
application in cancer treatment is a current hot research topic
in plasma medicine (see section 4.3). However, to realize
clinical use of CAP in the field of cancer treatment, some
preconditions have to be fulfilled, above all, regarding its applicability and safety. Beside proving CAP selectivity against
cancer cells (see section 4.3), another important question
surrounds a possible induction of cancer cell growth and
proliferation—comparable to the CAP effect in tissue regeneration—with the final consequence of metastasis, if subefficient CAP treatment intensity e.g. in the edge zone of plasma
impact, occurs. The first in vitro studies give evidence that the
latter danger is low [301, 302]. Other in vivo studies demonstrated that CAP treatment can enhance tissue oxygenation
and modulate blood flow (see section 4.2). On the one hand,
this may support metastasis. On the other hand, effects of
radiotherapy and chemotherapy may be enhanced in combination treatments. Several synergistic effects of CAP with
radiotherapy, PEF, or chemotherapeutics are demonstrated in
vitro as well as in animal experiments; see e.g. [303–309].
Such combination treatments are under investigation because
they offer the chance to reduce effective doses of radiation or chemotherapeutics, respectively, and by this means
lower side effects of cancer therapy. Another possible clinical setup is a supportive plasma application to treat the operation field of surgical tumour resections to remove possibly
remaining tumour cells in cases where large-scale surgical
tumour removal is impossible [310–312]. CAP application
in melanoma treatment is another field of long-term research
because melanomas typically occur in the skin and are therefore easily locatable and amenable for direct plasma treatment;
see e.g. [3, 304, 313, 314]. Due to the potentially induced
ICD by plasma (see section 4.3), the melanoma treatment efficacy may be enhanced by combining CAP together with established immunotherapies for metastasized melanoma treatment.
Moreover, induction of ICD may open up new perspectives on
CAP application for systemic cancer treatment.
However, even if more research has to be done to decide
if and under which circumstances therapeutic CAP applications for cancer treatment are promising and realistic in clinical
practice, the first clinical applications in specific fields were
realized yet. Utilizing especially the antimicrobial plasma
effect, CAP application was successful in the palliative care
of patients with advanced squamous cell carcinoma of the
head and neck, suffering infected tumour ulcerations. As the
main intended result, the microbial load and the resulting
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typical fetid odour was reduced. Besides additional pain reduction, in some particular cases, transient tumour remission also
occurred [17, 315, 316]. However, tumour growth relapsed
and the reasons for this effect not enduring in CAP-supported
tumour reduction needs to be found [317].
In the treatment of actinic keratosis, a precancerous skin
disease which can develop if left untreated, in skin cancer
called squamous cell carcinoma, CAP achieved good results
in the first patient studies [318–321].
The state of knowledge on CAP effects on cancer cells,
including immunostimulatory effects, together with the first
clinical applications, characterizes cancer treatment as the next
challenging but promising field of clinical CAP application
[322]. Further efforts have to be made to find out if CAP will
be able to mark a ‘paradigm shift in cancer therapy’ as was
predicted in 2011 [8].

transport medium to bring ROS/RNS from the plasma/gas
phase to the biological target (see section 4.2), but plasma
treatment of liquids also results in the enrichment of new
chemical species and subsequent changes of their biological
characteristics, making them useful for several applications.
Most research with respect to medical application of plasmatreated liquids has been done in cancer treatment. Here, two
application strategies are followed: (i) direct injection into
bulk tumours, and (ii) injection/infusion into the peritoneal
cavity in the case of metastasized intraperitoneal tumours, socalled carcinomatosis. For more details, see review papers like
[93, 95, 214]. As with direct CAP application for cancer treatment, much more research is needed to bring plasma-treated
liquids into clinical therapy concepts. This is with regard to
safety aspects on the one hand [340]. On the other hand, the
classification of such plasma-treated liquids from a regulatory
point of view is currently an open question, which possibly
needs new and innovative ways of admission.

5.4. Other prospective fields

Most plasma devices currently applied in clinical settings or
under research for medical applications, respectively, are most
applicable on readily accessible places in the human body,
e.g. on skin or during open surgery. Another accessible place
is the eye. Even though a gentle disinfection of eye surfaces
by CAP was demonstrated several years ago [323], plasma
application in ophthalmology is a subject of little research
so far. It has been repeatedly demonstrated in some studies
in vitro and in first animal experiments, that CAP is effective to inactivate microorganisms without harmful effects on
the cornea [324–328]. In a case series including four patients
with therapy-resistant corneal ulcers, the clinical potential of
CAP to treat infections as well as ulcerations of the cornea was
demonstrated [329].
Another field of long-term research on CAP application is
oral medicine and dentistry. Here, several fields of application
are thinkable, ranging from implantology, treatment of perimplantitis, treatment of teeth and tooth root channels, treatment
of oral wounds and infections up to rather aesthetic applications such as tooth whitening; see for review [330–338].
Over the last 10–15 years there has been a growing number of
promising research results being documented. However, CAP
applications in clinical settings are rarely reported in the field
of oral medicine and dentistry. Obviously, CAP applications
have to demonstrate their benefit compared to the more or
less satisfactory established therapies in specific applications.
Because in most cases dental problems or diseases are not
as wearing or life-threatening as nonhealing chronic wounds
or cancers, the risk-benefit balance may be assessed in dentistry with a different emphasis compared to other medical
fields. Consequently, the realistic potential of CAP application
in oral medicine and dentistry has to be evaluated also from an
economic point of view [339].
Finally, an intensively researched field hat is not a direct
CAP application in medicine is the use of plasma-treated liquids, frequently called PTS, plasma-conditioned liquids, PAL,
plasma-activated water (PAW), or plasma-activated medium
(PAM). Plasma-induced chemistry was explained in detail
in section 3. Liquid phases do not only serve as a transient

6. Perspectives on plasmas for medical
applications
Over the years, our understanding of plasma medical applications has continuously increased thanks to the constant efforts
of an ever-growing scientific community. Years of multidisciplinary research have laid out solid scientific foundations
which have recently started to pay off in terms of development and impact of the technology, as demonstrated by the
licensing and commercialization of several plasma sources as
medical devices (see section 5.1). After covering these foundational aspects in the previous sections, here we want to highlight what, in our opinion, is still unexplored and pivotal to
consider for further developing plasma technology for medical
applications. We identified four major challenges: (1) the regulatory challenge, dealing with licensing of plasmas as medical
devices apt for clinical use; (2) the cavity challenge, dealing
with the development of plasma technologies suitable for treatments in internal cavities of the human body; (3) the dose
challenge, dealing with the definition of a concept of dose for
medical applications of plasmas; (4) the monitoring and control challenge, dealing with ensuring controlled and repeatable
plasma treatments in clinical settings. These challenges often
overlap with each other, as in the case of the lack of specific
regulations for plasma devices for the treatment of internal
cavities of the body. For the sake of clarity, we decided to
treat these topics separately in the following, pointing out the
connections where needed.
6.1. The regulatory challenge

Regulations of medical devices are intended to guarantee
their safety and are rooted in the analysis of the risks associated with the technology under consideration. At the early
stage of development of plasma technologies for medical
applications, the need to take into account safety aspects
was already well understood [3]. The awareness of these
aspects grew over the years, with an increasing number of
papers referring to the need to consider the compliancy with
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regulations in the development of plasma devices [341–343]
and citing several documents for the analysis of associated
risks [344, 345]. The matter was complicated by the local
nature of regulations, often different from country to country, and the exponential increase of activity in the field,
resulting in many different plasma sources intended for a
plethora of different medical applications. In this context,
the year 2014 saw the introduction of the DIN SPEC 91315
[346], a specification registered by the German Institute of
Standardization (DIN) and indicating the criteria for the
characterization of different plasma devices intended for medical applications. The specification was meant to complement
the safety evaluation requirements indicated in the DIN EN
60601-1 [345] by introducing standards for the characterization of plasma sources in order to (i) obtain systematic and
comparable results from researchers all over the world and
(ii) produce results that could be checked against the safety
limits imposed by regulations not specifically developed for
plasma technology and that could vary from country to country
[344, 347, 348]. The test procedures proposed in the DIN
SPEC 91315, in accordance with already available standards
[349–354], encompass the measurements of temperature, UV
irradiance, emitted gas species, chemical species in liquids,
leakage current, antimicrobial activity and cytotoxicity. This
specification has been proven as a useful stepping stone for the
regulatory approval of plasma sources as medical devices and
is, overall, an accepted instrument with several publications
reporting the characterization of plasma devices according to
its standard procedures [355–357]. Despite all these positive
aspects, this specification is rooted in risk analysis performed
for plasma devices intended for dermatological applications
[358, 359]; as a consequence, the indicated methodologies
do not specifically address plasma devices intended for intrabody medical procedures. It should nonetheless be noted that,
considered its evolutive nature, the DIN SPEC 91315 could
be adapted in the future to account for specificities of intrabody plasma delivery and the associated clinical applications.
Also, the DIN SPEC 91315 does not cover the regulatory
aspects of plasma-treated liquids. This rarely mentioned aspect
[339, 360] is particularly thorny since plasma-treated liquids
intended for indirect medical applications can arguably be considered as pharmaceutical compounds, which are associated
with harsh regulations, strict manufacturing procedures and
the need to univocally identify active principles. It is the opinion of the authors that a discussion on this matter, first among
the scientific community and then involving regulatory bodies,
is urgent.

even more attention for the case of intrabody plasma application with respect to cutaneous application are electromagnetic
compatibility, leakage currents, gas delivery and plasma stability. While these constraints have been faced before and were
overcome by the plasma community during the development
of endoscopic plasma coagulators and ablators [362–366], the
nondestructive nature of medical applications of CAP creates
an unprecedented challenge. The endoscopic application of
CAP was first reviewed by Robert et al [367], who classified the different configurations described in literature as capillary DBD, hollow core fiber plasma jets and plasma guns
[219, 368–370]. Of these configurations, the latter was
arguably the subject of the most studies regarding its characterization and its effects in both in vitro and in vivo settings
[10, 203, 371, 372], confirming the possibility of creating flexible plasma devices capable of exerting biological effects in
intrabody settings. More recently, requirements such us material erosion, leakage currents and gas delivery started to be the
target of investigation for a new endoscopic plasma source,
whose architecture shows several similarities with thermal
plasma endoscopic coagulators [373, 374]. Major outcomes of
these works are the need for an electronegative shielding gas
to prevent the jet-to-glow transition of the discharge, strategies to prevent the formation of parasitic discharges within the
plasma device and at the high voltage connections, as well as
to limit the erosion of the materials during operation. Despite
these advancements, to the best of our knowledge there are currently no endoscopic CAP sources licensed as medical devices.
Following the footsteps of plasma devices for dermatological
applications, the road towards preclinical and clinical studies
will require the production of an ample body of documentation regarding the characterization, the safety and the biological efficacy of endoscopic plasma sources. A standardization
of procedures, adapting and extending the DIN SPEC 91315,
would prove instrumental to reach this goal.
6.3. The dose challenge

The term ‘dose’ refers to the quantity of a therapeutic agent
or of radiation, in the case of radiotherapy, administered to
the patient during a treatment. Medical doctors rely on this
concept when considering the therapeutic window of a certain
drug/treatment, whose boundaries are defined by the minimum
quantity required to exert the desired biological effects (minimum effective dose) and the maximum quantity not eliciting
unacceptable toxic effects (maximum tolerated dose). Moreover, the dose offers a standard to compare different treatments and is a suitable control parameter, since it connects
the inputs (the administered quantity of therapeutic agent) with
the outputs (the biological effects) of the process. In the context of plasma medical applications, dose initially referred to
the interrelated parameters of treatment time, power coupled
with the discharge and energy dissipated in it [152, 375–382].
As the understanding of the fundamental mechanisms driving plasma medical applications progressed over the years,
the dose became a controversial concept, with increasing discussions on the limitations of an energy-related definition
[111, 184]. A more refined concept of dose was recently

6.2. The cavity challenge

Several prospective medical applications of plasmas, chief
among which are oncological applications [361], envision
intrabody plasma delivery. Plasma devices intended for this
scope face peculiar constraints. Beside the requirement of biological efficacy, which is a challenge in itself given the variability of conditions at the site of application, plasma devices have
to be flexible and composed of materials with a limited rate of
erosion when contacting the plasma. Other aspects that require
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proposed. It relies on the equivalent total oxidation potential
(ETOP) and the bacterial reduction factor [133]. The ETOP
accounts for the oxidation potential of (i) the reactive species
produced in the discharge and flowing towards the target; (ii)
the other agents associated with the plasma discharge, such as
UV radiation and electric fields; and (iii) the synergistic effects
of the previous two factors, and was shown to be a promising
instrument to predict the bactericidal potential of some plasma
sources. Nonetheless, a comprehensive description of dose
through the ETOP parameters faces many obstacles. First of
all, determining the oxidation potential of the reactive species
requires the measurement of their flow towards the substrate
in real time, posing significant challenges in terms of process
monitoring. Second, quantitatively determining the oxidation
potential of agents other than reactive species is complicated.
Third, determining the oxidation potential associated with the
synergistic effects would require a complete mechanistic comprehension of the plasma biomedical processes. Furthermore,
the proposed parameter does not account for the oxidation
potential of the reactive species produced in the liquid environment surrounding the tissues and has yet to be shown to
be suitable for therapeutical applications different from disinfection. As a final note, data-driven machine learning techniques have recently been proposed as useful means to support
in the identification of a suitable parameter to be employed
as the dose for plasma medical applications, or as a possible
strategy to altogether circumvent the need for a definition of
dose [383].

for these issues, and also in the field of plasma medical applications [383, 389]. These techniques seem to offer interesting
avenues for identifying correlations between input and output
parameters, for highlighting patterns among large amounts of
data-produced monitoring plasmas and for enabling suitable
feedback control strategies [390]. Only the first steps have been
taken on this path and the road ahead is littered with scientific
questions and nontrivial technological challenges.

7. Summary
Plasma medicine, i.e. the use of cold atmospheric-pressure
plasma (CAP) directly on or in the human or animal body
for therapeutic purposes, has made tremendous progress over
the last decade. Even if a large number of different CAP
devices is in experimental or clinical application, two basic
types are dominating: DBD and APPJs. A common feature
of all CAP devices is that they are working under ambient air
conditions or, in several cases, using ambient air as the working gas for plasma generation. This results in the generation
of reactive oxygen and nitrogen species (ROS, RNS) which
were identified as the most important plasma agents causing
specific biological effects of CAP. The composition and quantity of ROS/RNS in plasmas depends on the diverse physical
and technical parameters of the plasma-generating devices as
well as on ambient conditions and plasma contact with other
media beyond atmospheric air, above all, liquid phases. Therefore, the biological performance of CAP devices may vary in
detail. However, plasma-generated ROS/RNS are similar to
those occurring as part of the metabolism in living organisms
and play several roles in cellular physiology and biochemistry.
Therefore, redox biology serves as a scientific basis to decipher and understand molecular mechanisms of biological CAP
effects and its medical use. Moreover, because of the physiological occurrence of ROS/RNS, mammalians (as humans are)
in particular are able to control its concentration in cells and
tissue and largely prevent any harmful effects of these species.
Above all, mutagenic and genotoxic effects can be excluded if
CAP devices are applied adequately.
CAP application in wound healing is on its way into clinical routine. The first CAP devices are approved for this field
of medical application. Mainly in chronic wounds, the unique
combination of the broad-spectrum antimicrobial effectivity
of CAP with a direct stimulation of tissue regeneration contributes to physiological wound healing that may be disturbed
by other diseases. Another important feature of CAP is its ability to induce regulated cell death in mammalian cells dependent on CAP treatment intensity. This is also true for cancer
cells. Even if CAP application in cancer treatment is still currently at the preclinical research stage, it is to be expected that
it will be the next step in clinical plasma application.
Today it has to be stated that the medical application
of CAP, which was primarily facilitated by physicists, has
become a transdisciplinary research field combining expertise from plasma physics, life sciences, and medicine. This
close cooperation is the key to ongoing successful research
and development leading not only to new options in medical

6.4. The monitoring and control challenge

Clinical applications of plasmas require repeatable and safe
treatments, often creating the need for refined process control strategies. More specifically, the typically nonlinear
relation between the process inputs (plasma parameters) and
outputs (the biological effects) can be tackled with feedback
control strategies. This means the creation of a loop where
process inputs are adapted as a function of the process outputs; an example of this strategy has been previously reported
for the case of a plasma jet and a simplified set of process
parameters [384]. Controlling strategies, in principle, require
an understanding of (i) which are the relevant parameters
controlling the process; (ii) what is the relationship between
inputs and outputs of the process; and (iii) monitoring those
inputs and outputs. In the case of plasma technologies, each of
these points is a challenge in itself, since the process presents
multiple variables (active principles) with synergistic effects
and the understanding of the fundamental mechanisms driving plasma-induced biological effects is still incomplete. Last
but not least, real-time monitoring of plasma devices is often
impossible in a clinical setting with conventional diagnostic techniques, either due to their nature, as in the case of
LIF or mass spectroscopy for measuring gas phase reactive
species, or due to the computational time required to elaborate the data acquired with more suitable techniques, such as
OES. Stimulated by the increasing use of machine learning
strategies in medicine [385–388], artificial intelligence datadriven approaches have been proposed as a potential solution
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therapy but also to a sound scientific basis for the innovative
field of plasma medicine.

[20] Metelmann H-R, von Woedtke T and Weltmann K-D (ed)
2018 Comprehensive Clinical Plasma Medicine (Berlin:
Springer)
[21] Toyokuni S, Ikehara Y, Kikkawa F and Hori M 2018 Plasma
Medical Science (London: Academic)
[22] Keidar M 2020 Plasma Cancer Therapy (Cham, Switzerland:
Springer Nature)
[23] Massines F, Rabehi A, Decomps P, Gadri R B, Ségur P and
Mayoux C 1998 J. Appl. Phys. 83 2950
[24] Kogelschatz U, Eliasson B and Egli W 1997 J. Physique IV 7
C4–47–C4–66
[25] Kogelschatz U 2003 Plasma Chem. Plasma Process. 23 1–46
[26] Kogelschatz U 2002 IEEE Trans. Plasma Sci. 30 1400–8
[27] Brandenburg R 2017 Plasma Sources Sci. Technol. 26 053001
[28] Laroussi M, Lu X, Kolobov V and Arslanbekov R 2004 J. Appl.
Phys. 96 3028
[29] Lu X, Reuter S, Laroussi M and Liu D 2019 Non-equilibrium
Atmospheric Pressure Plasma Jets: Fundamentals, Diagnostics, and Medical Application (Boca Raton, FL: CRC
Press)
[30] Teschke M, Kedzierski J, Finantu-Dinu E G, Korzec D and
Engemann J 2005 IEEE Trans. Plasma Sci. 33 310–1
[31] Lu X and Laroussi M 2006 J. Appl. Phys. 100 063302
[32] Mericam-Bourdet N, Laroussi M, Begum A and Karakas E
2009 J. Phys. D: Appl. Phys. 42 055207
[33] Sands B L, Ganguly B N and Tachibana K 2008 Appl. Phys.
Lett. 92 151503
[34] Walsh J L and Kong M G 2008 Appl. Phys. Lett. 93 111501
[35] Xiong Q et al 2009 J. Appl. Phys. 106 083302
[36] Karakas E, Koklu M and Laroussi M 2010 J. Phys. D: Appl.
Phys. 43 155202
[37] Naidis G V 2011 J. Phys. D: Appl. Phys. 44 215203
[38] Naidis G V 2010 J. Phys. D: Appl. Phys. 43 402001
[39] Yousfi M, Eichwald O, Merbahi N and Jomaa N 2012 Plasma
Sources Sci. Technol. 21 045003
[40] Boeuf J-P, Yang L L and Pitchford L C 2013 J. Phys. D: Appl.
Phys. 46 015201
[41] Karakas E and Laroussi M 2010 J. Appl. Phys. 108 063305
[42] Jarrige J, Laroussi M and Karakas E 2010 Plasma Sources Sci.
Technol. 19 065005
[43] Sakiyama Y, Graves D B, Jarrige J and Laroussi M 2010 Appl.
Phys. Lett. 96 041501
[44] Lu X, Naidis G V, Laroussi M and Ostrikov K 2014 Phys. Rep.
540 123–66
[45] Begum A, Laroussi M and Pervez M R 2013 AIP Adv. 3 062117
[46] Stretenovic G B, Krstic I B, Kovacevic V V, Obradovic A M
and Kuraica M M 2014 J. Phys. D: Appl. Phys. 47 102001
[47] Sobota A, Guaitella O and Garcia-Caurel E 2013 J. Phys. D:
Appl. Phys. 46 372001
[48] Laroussi M and Akan T 2007 Plasma Process. Polym. 4
777–88
[49] Lu X, Laroussi M and Puech V 2012 Plasma Sources Sci.
Technol. 21 034005
[50] Winter J, Brandenburg R and Weltmann K-D 2015 Plasma
Sources Sci. Technol. 24 064001
[51] von Keudell A and Schulz-von der Gathen V 2017 Plasma
Sources Sci. Technol. 26 113001
[52] Bruggeman P J, Iza F and Brandenburg R 2017 Plasma Sources
Sci. Technol. 26 123002
[53] Yue Y F, Mohades S, Laroussi M and Lu X 2016 IEEE Trans.
Plasma Sci. 44 2754–8
[54] Yonemori S and Ono R 2014 J. Phys. D: Appl. Phys. 47 125401
[55] van Gessel A F H, Alards K M J and Bruggeman P J 2013 J.
Phys. D: Appl. Phys. 46 265202
[56] van Gaens W and Bogaerts A 2013 Plasma Sources Sci. Technol. 23 035015
[57] Klose S-J, Manfred K M, Norman H C, Ritchie G A D and
van Helden J H 2020 Plasma Sources Sci. Technol. 29
085011

Acknowledgments
The authors would like to thank Professor Ronny Brandenburg for his valuable feedback and insightful suggestions. TvW gratefully acknowledges the financial support of
Research in Plasma Medicine by the Federal German Ministry of Education and Research (Grant Nos. 03Z22DN11
and 03Z22DN12). ML gratefully acknowledges the multiyear support he received from AFOSR, which allowed him to
develop his plasma medicine research.
Data availability statement
No new data were created or analysed in this study.
ORCID iDs
T von Woedtke https://orcid.org/0000-0002-1097-4832
M Laroussi https://orcid.org/0000-0001-6871-9001
M Gherardi https://orcid.org/0000-0001-6995-6754
References
[1] Lu X, Naidis G V, Laroussi M, Reuter S, Graves D B and
Ostrikov K 2016 Phys. Rep. 630 1–84
[2] Graves D B 2012 J. Phys. D: Appl. Phys. 45 263001
[3] Fridman G, Friedman G, Gutsol A, Shekhter A B, Vasilets V
N and Fridman A 2008 Plasma Process. Polym. 5 503–33
[4] Laroussi M 2009 IEEE Trans. Plasma Sci. 37 714–25
[5] von Woedtke T, Reuter S, Masur K and Weltmann K-D 2013
Phys. Rep. 530 291–320
[6] Weltmann K D, Kindel E, von Woedtke T, Hähnel M, Stieber
M and Brandenburg R 2010 Pure Appl. Chem. 82 1223–37
[7] Isbary G et al 2010 Br. J. Dermatol. 163 78–82
[8] Keidar M, Walk R, Shashurin A, Srinivasan P, Sandler A,
Dasgupta S, Ravi R, Guerrero-Preston R and Trink B 2011
Br. J. Cancer 105 1295–301
[9] Barekzi N and Laroussi M 2013 Plasma Process. Polym. 10
1039–50
[10] Vandamme M, Robert E, Pesnel S, Barbosa E, Dozias S, Sobilo
J, Lerondel S, Le Pape A and Pouvesle J-M 2010 Plasma
Process. Polym. 7 264–73
[11] Köritzer J et al 2013 PloS One 8 e64498
[12] Schlegel J, Köritzer J and Boxhammer V 2013 Clinical Plasma
Medicine 1 2–7
[13] Laroussi M 1996 IEEE Trans. Plasma Sci. 24 1188–91
[14] Laroussi M 2002 IEEE Trans. Plasma Sci. 30 1409–15
[15] Stoffels E, Flikweert A J, Stoffels W W and Kroesen G M W
2002 Plasma Sources Sci. Technol. 11 383–8
[16] Stoffels E, Kieft I E and Sladek R E J 2003 J. Phys. D: Appl.
Phys. 36 2908–13
[17] Metelmann H-R et al 2015 Clinical Plasma Medicine 3
17–23
[18] Laroussi M, Kong M, Morfill G and Stolz W 2012 Plasma
Medicine: Applications of Low-Temperature Gas Plasmas
in Medicine and Biology (Cambridge: Cambridge University Press)
[19] Fridman A and Friedman G 2013 Plasma Medicine (New York:
Wiley)

34

Plasma Sources Sci. Technol. 31 (2022) 054002

T von Woedtke et al
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Dejneka A and Lunov O 2020 Int. J. Mol. Sci. 21 6226

[134] Privat-Maldonado A, Schmidt A, Lin A, Weltmann K-D,
Wende K, Bogaerts A and Bekeschus S 2019a Oxid. Med.
Cell. Longevity 2019 1–29
[135] Fluhr J W, Sassning S, Lademann O, Darvin M E, Schanzer S,
Kramer A, Richter H, Sterry W and Lademann J 2011 Exp.
Dermatol. 21 130–4
[136] Hasse S, Duong Tran T, Hahn O, Kindler S, Metelmann H-R,
von Woedtke T and Masur K 2016 Clin. Exp. Dermatol. 41
202–9
[137] Collet G, Robert E, Lenoir A, Vandamme M, Darny T, Dozias
S, Kieda C and Pouvesle J M 2014 Plasma Sources Sci.
Technol. 23 012005
[138] Kisch T, Schleusser S, Helmke A, Mauss K L, Wenzel E T,
Hasemann B, Mailaender P and Kraemer R 2016 Microvasc.
Res. 106 8–13
[139] Kisch T, Helmke A, Schleusser S, Song J, Liodaki E, Stang F
H, Mailaender P and Kraemer R 2016b Microvasc. Res. 104
55–62
[140] Borchardt T, Ernst J, Helmke A, Tanyeli M, Schilling A
F, Felmerer G and Viöl W 2017 Microcirculation 24
e12399
[141] Daeschlein G, Rutkowski R, Lutze S, von Podewils S, Sicher
C, Wild T, Metelmann H-R, von Woedkte T and Jünger M
2018 Biomed. Eng.-Biomed. Tech. 63 603–8
[142] Schmidt A, Niesner F, von Woedtke T and Bekeschus S 2021
IEEE Trans. Rad. Plasma Med. Sci. 5 412–9
[143] Schmidt A, Liebelt G, Nießner F, von Woedtke T and
Bekeschus S 2021 Redox Biol. 38 101809
[144] Szili E J, Hong S-H, Oh J-S, Gaur N and Short R D 2018 Trends
Biotechnol. 36 594–602
[145] Babaeva N Y and Naidis G V 2018 Trends Biotechnol. 36
603–14
[146] Lu X, Keidar M, Laroussi M, Choi E, Szili E J and Ostrikov K
2019 Mater. Sci. Eng., R 138 36–59
[147] Lackmann J-W et al 2018 Sci. Rep. 8 7736
[148] Lackmann J-W et al 2019 PLoS One 14 e0216606
[149] Heusler T, Bruno G, Bekeschus S, Lackmann J-W,
von Woedtke T and Wende K 2019 Clinical Plasma
Medicine 14 100086
[150] Wenske S, Lackmann J-W, Bekeschus S, Weltmann K-D,
von Woedtke T and Wende K 2020 Biointerphases 15
061008
[151] Wenske S, Lackmann J-W, Busch L M, Bekeschus S,
von Woedtke T and Wende K 2021 J. Appl. Phys. 129
193305
[152] Kalghatgi S, Friedman G, Fridman A and Clyne A M 2010
Ann. Biomed. Eng. 38 748–57
[153] Ma Q 2013 Annu. Rev. Pharmacol. Toxicol. 53 401–26
[154] Victor P, Sarada D and Ramkumar K M 2020 Eur. J. Pharmacol. 886 173395
[155] Hiebert P and Werner S 2019 Int. J. Mol. Sci. 20 3856
[156] Schmidt A and Bekeschus S 2018 Antioxidants 7 146
[157] Schmidt A, Dietrich S, Steuer A, Weltmann K-D, von Woedtke
T, Masur K and Wende K 2015 J. Biol. Chem. 290 6731–50
[158] Arndt S, Schmidt A, Karrer S and von Woedtke T 2018 Clinical Plasma Medicine 9 24–33
[159] Schmidt A, von Woedtke T, Vollmar B, Hasse S and Bekeschus
S 2019 Theranostics 9 1066–84
[160] Arjunan K, Sharma V and Ptasinska S 2015 Int. J. Mol. Sci. 16
2971–3016
[161] Boxhammer V, Li Y F, Köritzer J, Shimizu T, Maisch T,
Thomas H M, Schlegel J, Morfill G E and Zimmermann J
L 2013 Mutat. Res. Genet. Toxicol. Environ. Mutagen 753
23–8
[162] Kluge S, Bekeschus S, Bender C, Benkhai H, Sckell A, Below
H, Stope M B and Kramer A 2016 PLoS One 11 e0160667
[163] Wende K, Bekeschus S, Schmidt A, Jatsch L, Hasse S,
Weltmann K D, Masur K and von Woedtke T 2016 Mutat.
Res. Genet. Toxicol. Environ. Mutagen 798–799 48–54
36

Plasma Sources Sci. Technol. 31 (2022) 054002

T von Woedtke et al

[238] Pervez M R, Begum A and Laroussi M 2014 Int. J. Eng.
Technol. 14 7–16
[239] Zhang Q, Zhuang J, von Woedtke T, Kolb J F, Zhang J, Fang J
and Weltmann K-D 2014 Appl. Phys. Lett. 105 104103
[240] Baharoglu Z and Mazel D 2014 FEMS Microbiol. Rev. 38
1126–45
[241] Bayles K W 2014 Nat. Rev. Microbiol. 12 63–9
[242] Li L, Mendis N, Trigui H, Oliver J D and Faucher S P 2014
Front. Microbiol. 5 258
[243] Dong K, Pan H, Yang D, Rao L, Zhao L, Wang Y and Liao X
2020 Compr. Rev. Food Sci. Food Saf. 19 149–83
[244] Cooper M, Fridman G, Fridman A and Joshi S G 2010 J. Appl.
Microbiol. 109 2039–48
[245] Dolezalova E and Lukes P 2015 Bioelectrochemistry 103
7–14
[246] Daeschlein G et al 2014 Plasma Process. Polym. 11 175–83
[247] Zimmermann J L, Shimizu T, Schmidt H-U, Li Y-F, Morfill G
E and Isbary G 2012 New J. Phys. 14 073037
[248] Alkawareek M Y, Gorman S P, Graham W G and Gilmore B
F 2014 Int. J. Antimicrob. Agents 43 154–60
[249] Krewing M, Jarzina F, Dirks T, Schubert B, Benedikt J,
Lackmann J-W and Bandow J E 2019 J. R. Soc., Interface
16 20180846
[250] Lloyd G, Friedman G, Jafri S, Schultz G, Fridman A and
Harding K 2010 Plasma Process. Polym. 7 194–211
[251] Frykberg R G and Banks J 2015 Adv. Wound Care 4 560–82
[252] Kramer A, Hübner N-O, Weltmann K-D, Lademann J,
Ekkernkamp A, Hinz P and Assadian O 2008 GMS
Krankenhaushygiene Interdiszip. 3 Doc13 (https://egms.de/
en/journals/dgkh/2008-3/dgkh000111.shtml)
[253] Bernhardt T, Semmler M L, Schäfer M, Bekeschus S, Emmert
S and Boeckmann L 2019 Oxid. Med. Cell. Longevity 2019
1–10
[254] Gan L, Jiang J, Duan J W, Wu X J Z, Zhang S, Duan X R, Song
J Q and Chen H X 2021 J. Biophotonics 14 e202000415
[255] Isbary G et al 2012 Br. J. Dermatol. 167 404–10
[256] Brehmer F et al 2015 J. Eur. Acad. Dermatol. Venereol. 29
148–55
[257] Ulrich C et al 2015 J. Wound Care 24 196–203
[258] Assadian O, Ousey K J, Daeschlein G, Kramer A, Parker C,
Tanner J and Leaper D J 2019 Int. Wound J. 16 103–11
[259] Metelmann H-R, von Woedtke T, Bussiahn R, Weltmann K-D,
Rieck M, Khalili R, Podmelle F and Waite P D 2012 Am. J.
Cosmet. Surg. 29 52–6
[260] Heinlin J et al 2013 Wound Repair Regen. 21 800–7
[261] Vandersee S, Richter H, Lademann J, Beyer M, Kramer A,
Knorr F and Lange-Asschenfeldt B 2014 Laser Phys. Lett.
11 115701
[262] Stratmann B et al 2020 JAMA Netw. Open 3 e2010411
[263] Mirpour S, Fathollah S, Mansouri P, Larijani B, Ghoranneviss
M, Mohajeri Tehrani M and Amini M R 2020 Sci. Rep. 10
10440
[264] Moelleken M, Jockenhöfer F, Wiegand C, Buer J, Benson S
and Dissemond J 2020 JDDG J. der Deutschen Dermatol.
Gesellschaft 18 1094–101
[265] Chuangsuwanich A, Assadamongkol T and Boonyawan D
2016 Int. J. Lower Extremity Wounds 15 313–9
[266] González-Mendoza B et al 2019 Clinical Plasma Medicine 16
100094
[267] Cutting K F, White R J and Legerstee R 2017 Wound Medicine
16 40–5
[268] Hartwig S, Doll C, Voss J O, Hertel M, Preissner S and Raguse
J D 2017 J. Oral Maxillofac. Surg. 75 429–35
[269] Hartwig S, Preissner S, Voss J O, Hertel M, Doll C, Waluga
R and Raguse J D 2017 J. Cranio-Maxillofacial Surg. 45
1724–30
[270] Rutkowski R, Schuster M, Unger J, Metelmann I and Chien T T
T 2018 Cold atmospheric plasma in context of surgical site
infection Comprehensive Clinical Plasma Medicine: Cold

[204] Garg A D, Dudek-Peric A M, Romano E and Agostinis P 2015
Int. J. Dev. Biol. 59 131–40
[205] Rodríguez-Ruiz M E, Vanpouille-Box C, Melero I, Formenti S
C and Demaria S 2018 Trends Immunol. 39 644–55
[206] Miller V, Lin A and Fridman A 2016 Plasma Chem. Plasma
Process. 36 259–68
[207] Bekeschus S, Mueller A, Miller V, Gaipl U and Weltmann K-D
2018 IEEE Trans. Rad. Plasma Med. Sci. 2 138–46
[208] Khalili M, Daniels L, Lin A, Krebs F C, Snook A E, Bekeschus
S, Bowne W B and Miller V 2019 J. Phys. D: Appl. Phys.
52 423001
[209] Lin A et al 2019 Adv. Sci. 6 1802062
[210] Mizuno K, Yonetamari K, Shirakawa Y, Akiyama T and Ono
R 2017 J. Phys. D: Appl. Phys. 50 12LT01
[211] Mahdikia H, Saadati F, Freund E, Gaipl U S, Majidzadeh
K, Shokri B and Bekeschus S 2020 Oncoimmunology 10
e1859731
[212] Mohamed H, Esposito R A, Kutzler M A, Wigdahl B, Krebs F
C and Miller V 2020 Plasma Process. Polym. 17 e2000051
[213] Tanaka H, Ishikawa K, Mizuno M, Toyokuni S, Kajiyama H,
Kikkawa F, Metelmann H-R and Hori M 2017 Rev. Mod.
Plasma Phys. 1 3
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Dobnik D 2020 Trends Biotechnol. 38 1278–91
[227] Moisan M, Barbeau J, Moreau S, Pelletier J, Tabrizian M and
Yahia L ’H 2001 Int. J. Pharm. 226 1–21
[228] Moisan M, Barbeau J, Crevier M-C, Pelletier J, Philip N and
Saoudi B 2002 Pure Appl. Chem. 74 349–58
[229] von Keudell A et al 2010 Plasma Process. Polym. 7 327–52
[230] Gaunt L F, Beggs C B and Georghiou G E 2006 IEEE Trans.
Plasma Sci. 34 1257–69
[231] Lackmann J-W and Bandow J E 2014 Appl. Microbiol.
Biotechnol. 98 6205–13
[232] Bourke P, Ziuzina D, Han L, Cullen P J and Gilmore B F 2017
J. Appl. Microbiol. 123 308–24
[233] Lunov O, Zablotskii V, Churpita O, Jäger A, Polívka L, Syková
E, Dejneka A and Kubinová Š 2016 Biomaterials 82 71–83
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